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Summary 
Beyond its fundamental role in fulfilling the nutritional and energetic needs of the cell, 
metabolism has emerged as an important component of cellular regulatory processes which 
are central to diverse biological phenomena, ranging from cell differentiation to cancer and 
longevity. These metabolic pleiotropic roles often converge on the crosstalk with gene 
expression regulation which is sensitive to the availability of specific metabolites utilized for 
chromatin and RNA chemical modifications. These required metabolites are often assumed to 
freely diffuse into the nuclear space, with their key biosynthetic pathways mainly assigned to 
function elsewhere. However, considering that the intracellular environment is a rather viscous 
space where the free diffusion between the different compartments could be restricted, a 
significant question arises of how the nucleus ensures a reliable supply of these essential 
metabolites, especially as it is often a reaction-diffusion scenario and not only diffusion. Along 
these lines, the aim of the current PhD thesis was to explore the hypothesis that the nucleus 
could harbor extended metabolic networks, and not only individual enzymatic steps, for local 
production of nuclear-relevant metabolites. To examine this, firstly, nuclear proteomics data 
and nuclear localization signal motif analysis were utilized to assess the potentiality of a 
nuclear presence of the corresponding metabolic enzymes. Next, by employing stable isotope 
[U-13C]-based metabolomics analysis in isolated nuclei, we tracked an operational activity. 
Proximity ligation mass spectrometry for selected enzymatic players allowed us to examine 
their proximity interactome further corroborating a nuclear subcellular topology. Cumulatively, 
our data provided multi-level evidence for a functional metabolic pathway operating in a 
mammalian nucleus. The identified pathway is made of parts of the TCA cycle with 
intermediates having key roles in chromatin and RNA modifications, reflecting thus the 
presence of a metabolic nuclear niche ensuring a stable supply of essential metabolites with 
nucleus-relevant functionalities. 
The aforementioned crosstalk between metabolism and gene expression regulation 
highlights the importance of considering metabolic deregulations in pathophysiological 
conditions. Cancer metabolic alterations are a well-studied phenomenon. Yet, little is known 
for the metabolic physiology of residual cancer cells that survive treatment and contribute to 
cancer relapse. The current PhD thesis contributed to the characterization of the metabolic 
particularities of residual cancer cells derived from a mouse model of breast cancer. The 
analysis indicated that the residual cells, although phenotypically similar to their normal 
counterparts and despite the absence of oncogenes expression, preserved a tumorous 
metabolic memory with main characteristics of an enhanced glycolysis, deregulated TCA and 
urea cycle. Considering glycolysis’ central role, we next aimed at investigating the network-
wide metabolic responses upon inhibition of two important facilitators of the pathway, namely 
lactate dehydrogenase A and the monocarboxylate transporters 1 and 2, involved in lactate 
generation and transportation, respectively, in cancer cell lines. The results revealed opposite 
changes in metabolite concentration pools in glycolysis and TCA cycle intermediates between 
the two inhibitors treatment, and an overall lower biosynthetic flux. Interesting metabolic nodes 
were identified that could potentially be therapeutically exploited.  
Uncovering and understanding metabolic network activities in previously overlooked 
places, like the existence of a nuclear multistep metabolic network, or the perseverance in 
cancer regressed cells of a metabolic phenotype mnemonic to the tumorous state, can shed 
light on the hitherto unknown mechanisms of gene regulation and its interplay with the 
metabolic state of a cell.   
  
 
 
  
  
 
Zusammenfassung 
Neben seiner grundlegenden Rolle in der Versorgung der Zelle mit Nährstoffen und 
Energie, hat der Stoffwechsel sich als wichtiger Bestandteil regulatorischer Prozesse 
herausgestellt, welche eine zentrale Rolle in biologischen Vorgängen einnehmen, die von der 
Zelldifferenzierung bis hin zu Krebs und Langlebigkeit reichen. Diese metabolischen 
pleiotropen Rollen laufen oft beim Crosstalk mit der Genexpressionsregulierung zusammen, 
die auf die Verfügbarkeit metabolischer Intermediate reagiert, welche für die chemische 
Modifikation von Chromatin und RNA vonnöten sind. Obwohl bestimmte metabolische 
Enzyme im Zellkern gefunden wurden, die an der Biosynthese der benötigten Metaboliten 
beteiligt sind, werden die Hauptstoffwechselwege nach wie vor anderen Bereichen der Zelle 
zugeschrieben. Es wird daher angenommen, dass die erforderlichen Metaboliten frei in den 
Kern diffundieren. Diese Annahme führt jedoch zu erheblichen Einschränkungen bei der 
Effizienz der Modifikationen, da die erhöhte Viskosität der intrazellulären Umgebung die 
Diffusion sogar kleiner Moleküle einschränken könnte, benötigte Metaboliten von anderen 
Enzymen abgefangen werden könnten und besonders da chemische Modifikationen oft 
Reaktions-Diffusionsprozesse sind. In diesem Zusammenhang war es das Ziel der 
vorliegenden Doktorarbeit, die Hypothese zu untersuchen, dass der Zellkern ausgedehnte 
metabolische Netzwerke und nicht nur einzelne enzymatische Schritte für die lokale 
Produktion von kernrelevanten Metaboliten enthalten kann. Um dies zu untersuchen, wurden 
zunächst Zellkern-Proteomics-Daten und Kernlokalisierungssignalanalysen verwendet, um 
das Potenzial einer entsprechenden Präsenz von Stoffwechselenzymen im Kern zu 
bestimmen. Durch den Einsatz von stabilen Isotopen [U-13C]-basierten Fluxanalysen in 
isolierten Zellkernen wurde die  operative Aktivität verfolgt. Durch die Proximity-Ligations-
Massenspektrometrie für ausgewählte enzymatische Akteure im Stoffwechsel konnten wir ihr 
Proximity-Interaktom untersuchen, was eine subzelluläre Zellkerntopologie weiter 
untermauert. Zusammengefasst liefern unsere Daten einen mehrstufigen Nachweis für einen 
funktionellen Stoffwechselweg in einem Säugetierzellkern. Der identifizierte Weg besteht aus 
Teilen des TCA-Zyklus mit Intermediaten, die eine Schlüsselrolle bei Chromatin- und RNA-
Modifikationen spielen. Dies spiegelt das Vorhandensein einer metabolischen Zellkernnische 
wider, die eine stabile Versorgung mit essentiellen Metaboliten mit kernrelevanten 
Funktionalitäten gewährleistet. 
Der zuvor erwähnte Crosstalk zwischen Metabolismus und Genexpressionsregulation 
unterstreicht die Bedeutung der Berücksichtigung von Stoffwechsel-Deregulierungen bei 
pathophysiologischen Zuständen. Krebstypische Stoffwechselveränderungen sind ein gut 
untersuchtes Phänomen. Über die Stoffwechselphysiologie von Krebszellen, die sich 
zurückentwickeln, die Behandlung überleben und zu Rückfällen beitragen ist jedoch wenig 
bekannt. Die vorliegende Doktorarbeit trug zur Charakterisierung der metabolischen 
Besonderheiten solcher residualen Krebszellen in einem Mausmodell für Brustkrebs bei. Die 
Analyse zeigte, dass die residualen Krebszellen trotz der phänotypischen Ähnlichkeit zu 
normalen Zellen und der Abwesenheit der Expression von Onkogenen ein tumoröses 
metabolisches Gedächtnis mit erhöhter Glykolyse und dereguliertem Harnstoff- und TCA-
Zyklus bewahrten.  In Anbetracht der zentralen Rolle der Glykolyse untersuchten wir in 
Krebszellen die netzwerkweiten metabolischen Auswirkungen der Inhibierung zweier zentraler 
Vermittler in der Glykolyse. Dabei handelte es sich um die Lactatdehydrogenase A und die 
Monocarboxylat-Transporter 1 und 2, die an der Bildung beziehungsweise dem Transport von 
Lactat beteiligt sind. Die Ergebnisse zeigten entgegengesetzte Änderungen in den 
Konzentrationen von Glykolyse und TCA-Zyklus-Intermediaten nach der Inhibitorbehandlung 
und einen allgemein verringerten Biosynthesefluss. In diesem Zusammenhang wurden 
interessante Metaboliten identifiziert, die therapeutisches Potential haben könnten.  
  
 
Zusammengenommen haben die Entdeckung und das Verständnis von 
Stoffwechselaktivitäten in versteckten und bisher übersehenen Bereichen, wie die Existenz 
einer mehrstufigen Stoffwechselarchitektur im Zellkern oder das Fortbestehen des an 
Krebszellen erinnernde Stoffwechselzustand in eigentlich zurückentwickelnden Krebszellen, 
weitreichende Implikationen für die bisher unbekannten Mechanismen der Genregulation und 
ihr Zusammenspiel mit dem Stoffwechselzustand der Zelle. 
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Introduction  
Metabolism has often been viewed in a mono-perspective way, mainly reflecting the 
bioenergetic and nutritional requirements of the cell. However, over the past years a growing 
body of evidence points that metabolism is not simply a static bystander, rather an active 
component of many physiological processes. Being the most dynamic and environment 
sensitive level of cellular function, metabolism not only captures information that goes beyond 
the genome, it also mediates the environmental inputs into gene and protein regulatory 
responses. This is highlighted by the metabolic dependencies of epigenetic-related enzymes 
that utilize specific metabolites as substrates or co-factors for the chemical modifications on 
chromatin, as well as from the fact that cancer cells harbor particular metabolic characteristics 
that contribute to cancer growth, proliferation and evolution. The following introduction builds 
around these two aspects of metabolism presenting the current available knowledge and 
addresses open questions that initiated the research motivations of the current PhD thesis.   
Metabolism and gene expression regulation 
Metabolites and chromatin modifications 
Amongst the different levels of organismal and intracellular interactions, the crosstalk 
between metabolism and gene regulation has been an increasingly established phenomenon. 
From the work of Jacob and Monod1 in the 60s that led to the elucidation of lac operon, up to 
the characterization of more complex nutrient and hormonal sensing mechanisms and 
signaling cascades2, these studies have highlighted how changes in the (micro)environmental 
nutritional status lead to changes in gene expression in order for an organism to adapt. More 
recent findings, however, have highlighted a supplemental and more intimate relationship 
between metabolism and gene regulation through the epigenome. It is nowadays well 
established that DNA and histones bare chemical modifications which modulate chromatin 
structure and accessibility, and in turn gene expression. These modifications, as well as their 
deposition and removal from the epigenetic modifying enzymes, require specific metabolites 
functioning as substrates or co-factors that are key intermediates of metabolism. Of the most 
well-known modifications, DNA and histone methylation depends on S-adenosyl methionine 
(SAM) as a methyl donor substrate, while the inverse reaction, the removal of methyl groups, 
is mediated by demethylases that make use of flavin adenine dinucleotide (FAD) or alpha-
ketoglutarate as co-factors. Accordingly, acetyl-CoA is the universal acetyl donor for histone 
acetylation, while a certain class of deacetylases, the sirtuin family of proteins, are dependent 
on NAD+ as a co-factor to exert their function. The list of the modification types and the relevant 
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needed metabolites is not exhausted to the above mentioned. Additional marks have been 
described and are continuously discovered, including various modifications especially on 
histone core and tails, like succinylation, propionylation, malonylation, butyrylation, 
crotonylation, glutarylation, citrullination, O-GlcNAcylation, poly(ADP) ribosylation3, or the 
most recently characterized histone serotonylation4.   
These metabolic dependencies of chromatin modifications connote that the metabolic 
physiology of a cell may, through the availability of particular metabolites, drive changes in 
chromatin, and in this way contribute to modulations in gene expression. Despite this being a 
rather logical connection, it remained largely underexplored, partially because it was not 
known whether the concentrations, or the range of variation, of these epigenetic-related 
metabolites could become limiting for the epigenetic-modifying enzymes. In other words, it 
was unclear whether the epigenetic modifying enzymes behave similar to the metabolic 
enzymes, whose activities are dependent on the metabolite abundances, or resemble mostly 
to kinases whose activities are independent of the levels of their substrate, the ATP, at least 
for most cases5,6. However, many rapid discoveries over the past decade started to provide 
evidence that variations on the metabolite concentration levels could indeed impact the 
respective epigenetic modifications.  
It has been shown that acetyl-CoA abundance levels can influence both global histone 
acetylation levels, as well as histone acetylation at specific genes. Along these lines, 
alterations in glycolytic flux result in similar alterations in acetyl-CoA pools and subsequently 
in histone acetylation levels7–9. In multiple mammalian cell lines, the regulation of histone 
acetylation by glucose availability was found to be dependent on the activity of ATP-citrate 
lyase (ACLY)7, the enzyme that produces acetyl-CoA from citrate. Under specific conditions, 
connected mostly to metabolic stresses like in hypoxic or nutrient-limiting environments, 
acetate can be utilized as an alternative carbon source for the production of acetyl-CoA and 
subsequently for histone acetylation through the activity of acetyl-coenzyme A synthase 2 
(ACSS2)10,11. The same enzyme was identified as the predominant contributor of acetyl-CoA 
generation for histone acetylation in mouse hippocampal neuronal cells12, highlighting that the 
relative pathways contributing to histone acetylation can be differentiated by cell type and 
physiology state. In addition, ACSS2 was found to be important for the recycling of acetate 
produced by histone deacetylases (HDACs)11. Apart from global acetylation, acetyl-CoA 
abundance levels have also been implicated to influences of histone acetylation of specific 
genes, for instance genes related to glycolysis, growth and proliferation7,13, as well as neuronal 
genes12.  
Similarly to acetyl-CoA, fluctuations in S-adenosyl methionine (SAM) concentration 
can impact total methylation levels. Studies have shown that decrease in the concentration of 
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SAM as a result of depletion in metabolites directly contributing to its generation, like 
methionine14, or threonine for the case of mouse embryonic stem cells15, has been connected 
to reduced methylation levels and induction of stem cell differentiation. Stem cells pluripotency 
and differentiation has also been associated to demethylation dynamics through the action of 
another metabolite, that of alpha-ketoglutarate, which is a necessary co-factor for a specific 
family of demethylases. In mouse embryonic stem cells, increase in concentration levels of 
alpha-ketoglutarate promote demethylation contributing to pluripotency maintenance16. On the 
contrary, in human primed pluripotent stem cells, alpha-ketoglutarate supplementation leading 
to global histone and DNA demethylation has the opposite cell fate effect, supporting stem cell 
differentiation17, italicizing thus how the same mechanism exerts a differential outcome 
depending on context-specificity. Around the same epigenetic node, the metabolites 
downstream of alpha-ketoglutarate, namely succinate and fumarate, has been shown to inhibit 
the activity of the alpha-ketoglutarate demethylases, and in this way contribute to global 
hypermethylation, a recurring phenotype in tumors harboring mutations in succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) that lead to supra-physiological levels of 
those metabolites18. Similarly, D- and L-2-hydroxyglutarate, two metabolites produced by 
mutant versions of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2), and wild type lactate 
dehydrogenase (LDH) and malate dehydrogenase (MDH) promiscuous activities under acidic 
or hypoxic conditions, respectively, are also inhibitors of the alpha-ketoglutarate demethylases 
inducing similar hypermethylating effects18,19.  
Modifications on RNAs, both on coding and non-coding, require also specific 
metabolic intermediates and play key role in their stability and function representing thus 
multiple additional layers in gene expression regulation20. The most known RNA modifications 
involve methylations which require SAM as a methyl donor, however many others stem from 
more complex metabolic pools and combinations21. As such, potential threads between 
metabolism and RNA could also apply, in an analogy to those of histones and DNA. A recent 
work have highlighted in leukemia and glioma the involvement of D-2-hydroxyglutarate in the 
inhibition of the mRNA demethylase FTO, resulting in a global increase in the N6-
methyladenosine (m6A) mRNA modifications, which in turn renders mRNA transcripts unstable 
and prone to degradation, especially those associated with MYC/CEBPA pathways22. Another 
example involves the N4-acetylcytidine (ac4C) modification found in rRNAs and tRNAs, which 
requires at least acetyl-CoA as a donor of the acetyl moiety. Studies in Saccharomyces 
cerevisiae and Caenorhabditis elegans found that perturbations contributing in decreased 
concentration levels of acetyl-CoA result also in ac4C reduced levels23,24. The human RNA 
acetyltransferase responsible for the catalysis of this modification, namely NAT1025, has been 
found to bind CoA suggesting that the enzyme could be regulated by feedback inhibition26. 
While studies in this field have been limited so far, the aforementioned examples begin to 
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illuminate another level of complexity in gene regulation and yet another role for metabolism’s 
contribution into this.  
Nuclear topology of epigenetic-related metabolic enzymes 
It is evidently from the above that the cell nucleus relies on specific metabolites to 
confer chemical changes on DNA, RNA and histones. A common perception for the needed 
metabolites is to freely diffuse into the nucleus, given especially the large size of the nuclear 
pores. However, often neglected is the fact that the intracellular environment is a rather 
viscous space where the free diffusion of metabolites between the different compartments, 
like cytoplasm and nucleus, could be restricted. A significant emerging aspect is thus how the 
efficiency of the epigenetic enzymatic reactions is ensured regarding the required metabolite 
accessibility and availability. While compartment-specific metabolic measurements are 
difficult, recent studies have highlighted the existence of some enzymes involved in the 
generation of epigenetic-related metabolites inside the nucleus.  
Of the most prominent examples is the methionine adenosyltransferase II (MATII) 
which catalyzes the biosynthesis of SAM from methionine. In mammalian cells, MATII 
localizes in the nucleus where it associates with chromatin remodeling factors and locally 
supplies methyltransferases with SAM27. In yeast nucleus, the respective enzyme is part of a 
multi-enzymatic complex that additionally contains a pyruvate kinase, serine metabolic genes 
and an acetyl-CoA synthetase (SESAME complex, SErine-responsive SAM-containing 
Metabolic Enzyme complex). The complex interacts with methyltransferases providing them 
with SAM, and in this way combines the methylation and phosphorylation (through the activity 
of the pyruvate kinase) of histone H3 in specific genes in response to glucose availability 
through the glucose-derived serine28. 
Analogous to SAM, acetyl-CoA is locally synthesized in the nucleus through three 
distinct enzymatic players the contribution of which is mainly shaped from condition and/or 
tissue particularities. In mammalian cells, under nutrient and oxygen sufficient conditions, 
ATP-citrate lyase (ACLY), an enzyme that localizes both in the cytoplasm and in the nucleus, 
produces acetyl-CoA from citrate utilized for global, as well as gene-specific, histone 
acetylation as mentioned earlier7. Recently, ACLY has also been implicated to histone 
acetylation as a response to DNA damage induced by ionization. ACLY was found to 
synthesize acetyl-CoA used for histone H4 and H2A acetylation close to double-strand DNA 
breaks. Absence of ACLY, or prevention of ACLY entry into the nucleus, resulted in reduced 
histone acetylation and impairment of repair by homologous recombination29. Apart from 
ACLY, another enzyme involved in acetyl-CoA production in the nucleus is the pyruvate 
dehydrogenase complex (PDC), a complex traditionally encountered as of mitochondrial 
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topology only. In cancer cells, PDC was found to translocate from mitochondria into the 
nucleus for local acetyl-CoA production from pyruvate, especially during S to G2 cell cycle 
phase transition and as a response to growth stimulating factors, mild mitochondrial stresses30 
or during a specific developmental time window in mice embryos31. Additional evidence, 
implicate PDC as being part of a larger multi-enzymatic complex in the nucleus, involving the 
pyruvate kinase M2, the acetyltransferase p300 and the arylhydrocarbon receptor (AhR). 
Pyruvate synthesis by PKM2 is further utilized by PDC for the generation of acetyl-CoA which 
in turn is used by p300 for the acetylation of specific genes that are targets of AhR32. Finally, 
the third enzyme connected to a nuclear acetyl-CoA production is ACSS2 that makes use of 
acetate as a substrate. As it was mentioned in the above section, ACSS2 nuclear activity has 
been connected to conditions of metabolic stress10,11 or to specific tissues (i.e. neurons)12, as 
well as to nuclear reprocessing of acetate produced by histone deacetylases towards acetyl-
CoA local regeneration11.  
While the aforementioned examples refer to the activities of mostly singular enzymes 
in the nucleus, a recent study in mouse embryos characterized the existence of a functional, 
partial TCA cycle in the nucleus during zygotic genome activation31. The pathway covered all 
the enzymatic reactions from pyruvate up to alpha-ketoglutarate, combining thus the 
biosynthesis of two important epigenetic-related metabolites, that of acetyl-CoA and alpha-
ketoglutarate, highlighting in this way the actuality, within the nuclear compartment, of 
metabolic channeling facilitating chromatin modifications. The pathway was found to be absent 
from the nucleus in later stages and to localize only in the mitochondria, in alignment with the 
traditional perspective regarding the subcellular topology of TCA cycle enzymes. Interestingly, 
aconitase 2 (ACO2), one of the enzymes of the aforementioned pathway that catalyzes the 
citrate to isocitrate formation, is present in yeast nuclei with uncharacterized function so far33. 
The subsequent to ACO2 enzymatic step involving the isocitrate conversion to alpha-
ketoglutarate is facilitated by isocitrate dehydrogenase (IDH) which has three isoforms in 
mammalian cells. While their primary localization is assigned to mitochondria for IDH2 and 
IDH3, and cytoplasm for IDH1, both IDH1 and IDH3 appear to have a nuclear localization 
albeit in seemingly smaller pools and with yet unexplored function(s). Recently, another TCA 
cycle enzyme has been located in the nucleus of mammalian cell lines. The alpha-
ketoglutarate dehydrogenase complex (OGDC), that generates succinyl-CoA from alpha-
ketoglutarate, has been found to interact and supply the acetyltransferase KAT2A with 
succinyl-CoA. KAT2A in turn functions as a succinyltransferase mediating the succinylation of 
histones in gene promoter regions34. Finally, two additional TCA cycle-related enzymes that 
appear to have a nuclear localization are the succinate dehydrogenase (SDH) and fumarate 
hydratase (FH). SDH is a heterodimer consisting of SDHA and SDHB subunits mediating the  
Introduction: Beyond the mono-perspective view of metabolism 
  
24 
 
 
Figure 1: Paradigms of subcellular localization of metabolic enzymes related to the production of epigenetic 
relevant metabolites. 
conversion of succinate to fumarate in the mitochondria where it is also coupled to 
oxidative phosphorylation. Studies from the 60s have spotted both subunits in the nucleoli of 
cancer cells exhibiting an enzymatic activity, although that was not directly assigned to 
fumarate production35,36. Since then, the nuclear presence and potential functions of the 
heterodimer have not been further investigated. Finally, fumarate hydratase (FH), which 
catalyzes the reversible fumarate to malate reaction, was of the first mitochondrial TCA cycle 
enzymes to be described in the nucleus where its enzymatic activity was connected to 
chromatin modifications. More specifically, it has been shown that FH translocate to the 
nucleus in response to DNA damage induced by ionization37. Later it was found that the 
enzyme interacts with histones close to double strand DNA breaks and locally produces 
fumarate that inhibits histone H3 demethylation, setting in turn a sequence of events for 
recruitment of specific factors leading to DNA repair by non-homologous end-joining38.  
Cumulatively, the aforementioned paradigms begin to highlight that although 
metabolic intermediates diffuse into the nucleus, their local biosynthesis has biologically 
meaningful implications. As a consequence of this, many interesting aspects begin to emerge, 
for instance, the inquiry of the existence of more extended metabolic networks around 
epigenetic-related metabolites within the nuclear compartment, apart from only distinctive 
enzymatic steps. As an extension to the nuclear partial TCA cycle identified in mouse 
embryos, it is enticing to hypothesize the existence of multi-step metabolic organization 
coopted in additional cells and/or conditions that could allow for more efficient metabolic 
channeling, and/or allow for multiple pathway couplings regarding metabolite biosynthesis with 
nuclear relevant extensions.  
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Metabolism and cancer 
Although cancer metabolism was actively explored before the 1970s, the advent of 
genomic era with the molecular and genetic approaches has dampened the interest towards 
it. However, over the past decade cancer metabolism has been greatly reconsidered as it is 
now well established that cancer is not only the final outcome of genetic mutations, instead for 
its effective understanding non-genetic determinants must also be taken into account in a 
relationship that is not simply one of cause and effect. Cancer cells are characterized by 
metabolic particularities that offer them great robustness, enabling them to adapt and support 
their growth and proliferation even under limiting conditions by (re)shaping the pathway 
activities and their relative contributions39. These idiosyncrasies are mentored by both cell-
internal factors, representing metabolic network constraints mainly imposed by cancer 
genetics and tissue of origin, as well as external factors, referring to the microenvironment as 
it is shaped by nutrient and oxygen availabilities and the interactions with matrix and 
neighbouring cells40. Although there are no universal metabolic features common to all cancer 
types, there are still some general hallmarks39, whose interpretation in the context of the 
aforementioned internal and external to each cancer type factors could offer therapeutic 
opportunities.  
Pleiotropic roles of aerobic glycolysis in cancer cells 
Of these hallmarks, the most commonly recurring across many cancer types is an 
alteration in glucose metabolism41. In non-cancerous and non-proliferating mammalian cells, 
glucose is converted to pyruvate which upon entry in mitochondria is metabolized in TCA cycle 
and oxidized to CO2 yielding high amounts of ATP through oxidative phosphorylation. Cancer 
cells, as well as normal proliferating and developing cells, display an increase in glucose 
uptake which in turn is converted to lactate, even under oxygen replete conditions. 
Subsequently, lactate is secreted in the extracellular space. This phenomenon, known as 
aerobic glycolysis or the Warburg effect, was first described by Otto Warburg almost a century 
ago41,42. Recent studies have highlighted that aerobic glycolysis could be induced both by 
oncoproteins, like MYC, RAS or AKT, as well as by environmental inputs, such as growth 
factors40,43–46. However, despite the magnitude of studies, how exactly aerobic glycolysis 
promotes or contributes to cancer growth still remains unclear. Studies argue that glycolysis 
functions mainly by supporting the high energetic and biosynthetic requirements of cancer 
cells41. Although it is now well established that ATP is not a limiting factor for rapidly 
proliferating cells, which instead present only a slight increase in ATP consumption39, a major 
requirement is the reducing equivalents, more specifically NADPH47. The various branching 
pathways stemming from glycolysis can indeed couple the glycolytic function to the 
biosynthesis of NADPH, as well as to various other macromolecules like nucleotides, lipids 
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and amino acids such as serine and glycine. The latter two represent an example of glycolytic 
carbon divergence in certain cancers, where up to 50% of glucose contributes to their 
production through the rate-limiting enzyme phosphoglycerate dehydrogenase (PHGDH)48. 
Serine and glycine are in turn connected to various pathways such as generation of 
glutathione, NADPH, as well as SAM for epigenetic modifications. However, despite the above 
paradigm, a limitation for the generalization of the biosynthesis as the driving force of the 
aerobic glycolysis in cancer cells comes from the fact that biomass accumulation would require 
the glucose carbons to be retained and not secreted as lactate41, which in many cases 
accounts even for 93% of the glucose uptake49. These findings imply that biosynthesis could 
occur only in times of a very high glycolytic flux, and in turn lactate secretion helps to maintain 
the glycolysis active43.  
Additionally, the above numbers suggest that glycolysis may serve more functions, 
beyond bioenergetics and biosynthesis. Possible connections are now implicating lactate 
which has been shown to exert multifactorial effects. Lactate, through the acidification of the 
microenvironment, can promote disruption of the tissue architecture enabling thus tumour 
invasion50. In addition, lactate has been found to act as a signal for tumour-associated 
macrophages modulating their gene expression51. These altered macrophages can in turn 
induce tube-like morphogenesis in adjacent cells that allow blood perfusion in nutrient limited 
areas52. Recent studies have expanded even more the functional relevance of lactate, 
attributing to it a more centralized role, as it has been shown that is the primary carbon source 
for TCA cycle metabolites, both in normal tissues (in mice)53, as well as in lung cancer cells54. 
The studies showed that lactate’s turnover fluxes exceeded those of glucose both in fed and 
fasting mice, and that glucose contributed in TCA cycle through circulating lactate53. Lactate 
dehydrogenase that catalyses the reversible conversion of pyruvate to lactate exist as homo 
or heterotetramers of lactate dehydrogenase A and B (LDHA, LDHB) subunits. In HeLa cells, 
LDHB has a mitochondrial topology, in addition to the cytoplasmic, catalysing lactate oxidation 
to pyruvate and subsequent utilization in TCA cycle as well as in lipid biosynthesis55. These 
studies, further complement earlier models suggesting a symbiosis between glycolytic and 
oxidative tumour cells where lactate produced from one type is utilized by the other56. 
Cumulatively, lactate’s pleiotropic roles render him a potential therapeutic target with studies 
examining the inhibition of the enzymes catalysing its biosynthesis (LDH) or its transportation 
(monocarboxylate transporters, MCTs). So far, none of the developed LDH inhibitors have 
progressed into clinical trials, owing to inefficacies, to developed drug resistance or 
unacceptable toxicities57, while MCT inhibitors are currently being tested as an alternative40.  
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Mitochondria and TCA cycle in cancer 
Apart from aerobic glycolysis, the importance of mitochondrial metabolism to tumour 
proliferation is now beginning to emerge. It is well established that most cancer cells still 
maintain functional mitochondria whose relevance to cancer growth is highlighted by studies 
where depletion of mitochondrial DNA (mtDNA) reduces their tumorigenic potential58. 
Tumorigenesis is restored once cells acquire host mtDNA through a process that involve 
whole mitochondrial transferring from stroma cells59. Cells lacking mtDNA display a defective 
electron transport chain (ETC)60. Surprisingly, the feature that mainly contributes to the 
attenuation of their proliferation is not an ATP deficiency, as it was initially thought, rather the 
lack of electron acceptors from ETC whose presence is necessary for the continuation of 
enzymatic reactions involved mainly in nucleotide biosynthesis. More specifically, such 
reactions include the dihydroorotate dehydrogenase (DHODH)61, a rate-limiting enzyme 
whose activity is coupled to respiration and is involved in de novo pyrimidine synthesis, as 
well as the oxidation reactions in TCA cycle leading to aspartate generation which is an 
essential carbon and nitrogen donor for purine and pyrimidine biosynthesis62,63. As a result, 
targeting of electron transport chain64–66 and especially its combinatorial targeting with 
glycolysis57 are examined as alternative potent strategies for cancer growth inhibition.  
In addition to nucleotide biosynthesis, TCA cycle further contributes to other metabolic 
precursors which complement the ones generated from glycolysis. These precursors include 
non-essential amino acids as well as fatty acids. Fatty acids, in contrast to the majority of non-
cancerous tissues, present a high increase in many cancer cells and apart from being integral 
components in membrane synthesis they can also function as signalling molecules67. In 
mammalian cells, the most predominant pathway for their biosynthesis involves the citrate 
which is produced inside the mitochondria through TCA cycle and subsequently is exported 
to cytosol for generation of oxaloacetate and acetyl-CoA from ATP citrate lyase (ACLY). Part 
of acetyl-CoA is converted by acetyl-CoA carboxylase (ACC) to malonyl-CoA, the latter being 
the first committed step to fatty acid generation68. Both ACLY and ACC, along with the fatty 
acid synthase (FASN), have been found upregulated in human cancers, while their inhibition 
reduces cancer cell growth in vitro and in vivo67,69,70. This carbon divergence away from TCA 
cycle for lipogenesis necessitates its replenishment through additional nutrients in order for 
the cycle to continue the supply of other anabolic and energetic intermediates. As such, apart 
from glucose, a prominent anaplerotic carbon source is glutamine which feeds the TCA cycle 
mainly after conversion to glutamate and subsequently to alpha-ketoglutarate49. Oxidation of 
alpha-ketoglutarate in the cycle contributes to the generation of aspartate and citrate amongst 
other metabolites. Under specific contexts, associated with hypoxic conditions or defective 
mitochondria, glutamine contributes to the generation of citrate mainly through a reversal of a 
part of the TCA cycle, where alpha-ketoglutarate is reductively carboxylated to isocitrate and 
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then citrate, through the activities of isocitrate dehydrogenases (IDH1 or IDH2) and aconitase 
(ACO1 or ACO2), respectively71–73. Apart from a carbon donor, glutamine is also an important 
nitrogen source for nucleotide biosynthesis49. Most cancer cells in culture exhibit an increased 
dependence on glutamine anaplerosis49, and recent studies have highlighted that this feature 
can be regulated by oncoproteins, more specifically MYC74. Along these lines, inhibitors 
targeting glutaminase, the enzyme which converts glutamine to glutamate, are explored as 
therapeutic cancer interventions75.  
The aforementioned paradigms signify how classical central carbon metabolic 
pathways such as glycolysis and TCA cycle are deregulated to contribute to cancer growth 
and proliferation through novel and formerly underappreciated biological mechanisms. As 
already mentioned, these metabolic particularities are often additionally shaped by the tissue 
metabolic architecture and the tumour microenvironment76. As a result, the same oncogene 
can induce differential metabolic phenotypes along the same pathway in different tissues, and 
different cancerous tissues can employ differential nutrients or strategies for their acquisition 
and biosynthesis. This is illustrated in myc induced lung and liver cancers, where the first 
display an upregulation in glutamine uptake and catabolism, while the latter are characterized 
by increased glutamine synthesis and accumulation77. Regarding nutrient acquisitions, kras 
transformed lung cells can directly uptake branched chain amino acids (BCAAs) from the 
blood stream78, instead kras pancreatic tumours obtain them indirectly from extracellular 
proteins through macropinocytosis79. Lastly, in a manner dependent both on tumour 
microenvironment and tissue genetics, aspartate biosynthesis can derive either from 
glutamine through TCA cycle62,63, or from glucose through a sequence of reactions with fewer 
oxidative steps80. All the above emphasize the perplexity in identifying metabolic targets for 
cancer therapy since identical cells in distinctive microenvironments may exhibit differential 
metabolic phenotypes and variations in responses, for instance in drugs. Furthermore, given 
that the tumour microenvironment substantially differs from the more tractable one in in vitro 
cell culture systems challenges exist regarding the in vivo relativity of metabolic reprograming 
schemes and extensive verifications are required. This was recently highlighted in kras lung 
tumours - cancer cells derived from these tumours extensively utilized glutamine when 
cultivated in vitro, however for the respective in vivo tumours glutamine utilization was 
minimal80. Cell and tissue morphology may also influence nutrient accessibilities, so cell 
culture systems better resembling in vivo tissue morphology, for instance 3D cell cultures81, 
offer significant advantages when system controllability is required. Finally, although the 
substantial amount of studies over the last years have shaped many important aspects around 
cancer metabolism, much remains unknown for the metabolic idiosyncrasies of tumour 
dormant cells which contribute to cancer retrogression. Their characterization regarding 
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persisting and uniquely metabolic attributes is imperative for further understanding cancer 
pathophysiology and therapeutics. 
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Thesis Motivation and Objectives 
Every stage in the life of a human cell, from embryonic development to ageing, 
critically depends on precise regulation of gene expression. To achieve this highly complex 
task, the cell nucleus relies on specific metabolites utilized as substrates or cofactors to confer 
modifications on DNA, RNA and chromatin. Although certain metabolic enzymes related to 
the biosynthesis of these metabolites have been spotted in the nucleus, their key metabolic 
pathways, e.g. the tricarboxylic acid cycle, are mainly assigned to function in the cytoplasm or 
mitochondria. The metabolites required for these modifications are thus assumed to freely 
diffuse across the nuclear pores and within the nucleoplasmic space. However, considering 
that the intracellular environment is a rather viscous space where the free diffusion between 
the different compartments could be restricted, a significant question arises of how the nucleus 
ensures a reliable supply of these essential metabolites, especially as it is often a reaction-
diffusion scenario and not only diffusion. Towards these lines, the principle purpose of the 
current PhD thesis was to explore the hypothesis that the nucleus could harbor extended 
metabolic networks, and not only distinctive enzymatic steps, around epigenetic-related 
metabolites (Chapter I). The existence of nuclear multistep metabolic architecture, in an 
analogy to known metabolons described so far for other subcellular organelles, can reveal 
novel extensions in gene expression regulation and the interplay with the cellular metabolic 
state. 
The aforementioned metabolic dependencies of the epigenetic regulating enzymes 
suggest that the metabolic physiology of a cell may, through the availability of metabolites, 
drive changes in chromatin and in this way contribute to modulations in gene expression. As 
such, the metabolic alterations underlying many diseases, being either the outcome or the 
effect, may in turn have enabling, promoting, or reshaping activities on these disordered 
states. Along these lines, cancer metabolic particularities are now a well-established 
phenomenon presenting potential therapeutic interventions. Yet, far less is known for the 
metabolic physiology of residual, dormant cancer cells that contribute to cancer relapse. 
Understanding their metabolic pathophysiology is important as it may reveal mechanisms 
sustaining this population and signatures enabling their in vivo identification which in turn can 
lead in devised therapeutic strategies for their successful eradication. By employing a three-
dimensional cell culture system derived from a mouse model that carry inducible oncogenes 
(i.e. MYC/NEU), and thus able of simulating tumor progression, regression and relapse, the 
current thesis contributes to the characterization of the metabolic reformations of the residual 
population (Chapter II). Lastly, building around a well-established phenomenon present across 
many cancer types, that of aerobic glycolysis, the effects of two potent drug inhibitors involved 
in lactate generation and transportation are comprehensively addressed at the metabolic level 
(Chapter III).  
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Chapter I: Uncovering metabolic pathways operating in the 
mammalian nucleus 
The cell nucleus critically depends on metabolic factors for mitigating a precise 
regulation of gene expression82. Considering the large size of the nuclear pores, a common 
perception for these required metabolites is that they freely diffuse into the nuclear space, with 
their key metabolic pathways functioning elsewhere. However, often neglected is the fact that 
the intracellular environment is a rather viscous space where the free diffusion of metabolites 
between the different compartments could be restricted83, or metabolites could be siphoned 
to other metabolic processes until they reach the nuclear sites of need. This diffusion scenario 
in turn poses questions for the efficiency of the epigenetic enzymatic reactions and how it is 
ensured regarding the required metabolite accessibilities and availabilities. Recent studies 
started to highlight the existence of specific metabolic enzymes involved in the biosynthesis 
of epigenetic-related metabolites inside the nucleus. The most prominent paradigms include 
the nuclear production of SAM27, and acetyl-CoA which can be locally synthesized through 
three distinct enzymatic players the contribution of which is dependent on specific conditions 
and/or tissue particularities.7,30. These studies thus reveal that a local nuclear generation can 
have biologically meaningful implications. Along these lines, here, we opted to investigate the 
hypothesis that the nucleus harbors not only distinctive enzymatic steps, but extended 
metabolic networks which could increase the efficiency of substrate channeling conferring a 
more reliable supply of essential metabolites rate-limiting in the control of gene expression. 
We explored this by employing a combination of proteomics, [U-13C]-based stable isotope 
metabolomics and proximity labeling mass spectrometry to draft the potentiality and activity of 
the respective metabolic pathways.  
Nuclear Proteome and NLS motifs suggest a nuclear subnetwork made 
of TCA cycle enzymes 
As a first step of this study, we opted to explore literature-available proteomics 
datasets of isolated nuclei for the presence of metabolic enzymes. The proteomics data 
corresponding to nuclei isolated from five commonly used mammalian cell lines were obtained 
from Beck and colleagues84. Data were also available for crude cytoplasmic fractions referring 
to cytoplasm and all other subcellular compartments except the nucleus. 2146 metabolic 
enzymes covering 78 pathways of central carbon metabolism were extracted from KEGG 
database85–87 and used as a seeding dataset to search against the aforementioned nuclear 
data. In total, 181 enzymes (out of the 2146, ~8.5% coverage) were consistently detected in 
the nucleus of all five cell lines, while the respective number for the crude cytoplasmic fraction 
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was 567 enzymes (out of 2146, 27% coverage) (Figure 2). When the nuclear detected 
metabolic enzymes were mapped onto the KEGG pathways, we observed the presence of 
TCA cycle related enzymes (Figure 2a). The relative abundance distribution of the metabolic 
enzymes within the crude cytoplasmic fraction did not readily connect their nuclear presence 
to a cytoplasmic contamination as it seemed to be mostly concentration-independent (Figure 
2b). For instance, of the most abundant cytoplasmic enzymes, malate dehydrogenase 1 
(MDH1), aconitase 1 (ACO1) and isocitrate dehydrogenase 1 (IDH1) were not detected in the 
nuclear fractions. For the mitochondrial compartment and TCA cycle per se, enzymes with 
similar abundances in the crude cytoplasmic fraction were not equally present in the nucleus 
(i.e. PCK2 vs IDH3G, SUCLG2 vs OGDH). 
 
Figure 2: The nuclear metabolic proteome. (a) Metabolic enzymes detected in the crude cytoplasm (upper panel) 
and in the nucleus (lower panel). The line width corresponds to the relative abundance of the enzymes within the 
respective compartment. (b) Relative abundance distribution of the metabolic enzymes within the crude cytoplasm. 
The metabolic enzymes that are detected in the nucleus are depicted with red letters. (c) Top enriched metabolic 
pathways in the crude cytoplasmic and nuclear fractions. 
The reconstruction of parts of the TCA cycle in the nucleus was thus intriguing. As 
already discussed in the introduction, individual enzymes of the TCA cycle have a nuclear 
localization connected to the biosynthesis of metabolites utilized for histone and DNA 
modifications30,88. As such, the existence of larger networks that could facilitate more effective 
substrate channeling for a localized production of important metabolites might not come as a 
surprise. This idea of metabolons has already been studied for individual pathways, including 
TCA cycle, albeit within the more traditional mitochondrial perspective89–93. This prompted us 
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to further investigate the TCA enzymes for the presence of nuclear localization motifs (NLS) 
in their sequence which, although not a necessity, would provide additional evidence for the 
possibility of a nuclear topology. Except citrate synthase (CS), we identified NLS for every 
enzyme, or individual partners when it came to complexes, up to the generation of fumarate 
(Figure 3). In total, we identified NLS for 9 enzymes directly associated to TCA cycle, and for 
12 enzymes when a more extended network was included (Figure 3). Apart from OGDC34, 
none of the other enzymes had a previously characterized NLS. For PDC, which has been 
shown to localize in the nucleus with unknown mechanism so far30, we identified NLS for two 
subunits, namely PDHB and PDHA2, while for OGDC, we identified an additional NLS for the 
OGDH subunit, apart from the already described one on DLST34.  
 
Figure 3: Nuclear Proteome and Nuclear Localization Signal motifs suggest the potentiality of a nuclear 
subnetwork of TCA cycle enzymes. With light background are the enzymes detected in the nuclear proteomics 
datasets. A black box around the enzymes denotes the presence of Nuclear Localization Signal (NLS) in their 
sequence. Green letters represent the enzymes with a nuclear topology in Human Protein Atlas94,95 database. 
Enzymes proven by other studies to localize in the nucleus are depicted with a red dot. Enzymes with a condition-
specific localization in the nucleus are marked with a light red dot.  
Other NLS motifs for enzymes connected to TCA cycle anaplerosis included those for 
the pyruvate carboxylase (PC) and for aspartate aminotransferase (GOT2). Interestingly, we 
also identified NLS for two enzymes involved in fatty acid β-oxidation which is connected to 
acetyl-CoA production, namely the 3-ketoacyl-CoA thiolase (ACAA2) and the beta subunit of 
trifunctional enzyme (HADHB). To have an initial spatial resolution, we mapped the TCA cycle 
enzymes to the Human Protein Atlas94,95 and we found nuclear immunofluorescence evidence 
for a number of them, while two enzymes presented a cell line-specific nuclear topology (i.e. 
ACO2, PC). Figure 3 encompasses all the aforementioned information which, collectively, 
pointed towards the potentiality of a TCA cycle subnetwork present in the mammalian nucleus.  
 Chapter I: Uncovering metabolic activities in the mammalian nucleus 
 
 
38 
 
 [U-13C]-Glutamine and [U-13C]-Citrate label TCA cycle key intermediates 
delineating an active metabolic pathway operating in the HeLa nucleus 
The cumulating nuclear proteomics, NLS and imaging data described above indirectly 
inferred the possibility of a local nuclear production of specific TCA cycle-related metabolites 
by the presence of the corresponding enzymes. The quantification of the metabolites of 
interest would provide additional evidence, however, compartment-specific metabolic 
measurements are inherently difficult since metabolism readily changes upon experimental 
stresses during the laborious organelle isolation procedures. The fast turn-over rates of the 
metabolites along with their excessive diffusion through the membranes result in a non-
representative capture of the in vivo subcellular metabolic physiology and composition. 
Additionally, only the presence of an enzyme is not necessarily coupled to an 
enzymatic/metabolic activity. To directly assay the metabolic functionality of such a network, 
we therefore decided to introduce in isolated nuclei heavy isotope (13C) labeled compounds 
representing key entries and nodes of TCA cycle, and trace labeled carbon incorporation to 
the following metabolites.  
Our experimental scheme (Figure 4) involved the isolation of nuclei from HeLa cells, 
incubation with uniformly 13C-labeled substrates (U-13C) for 1 or up to 5 hours, harvesting and 
washing with PBS to remove any extra-nuclear contaminants, and finally collection for 
metabolomics analysis. Polar metabolites were extracted from the collected nuclei and the 
mass isotopomers of TCA cycle intermediates were quantified by Gas Chromatography - Mass 
Spectrometry (GC-MS). In parallel, total cell lysates (lysed cells corresponding to a mixture of 
cytoplasm with all subcellular compartments, some partially lysed and some intact) were 
incubated under the same buffer and conditions, serving as a positive control for the labeling 
tracing. Finally, to assess the purity of the isolated nuclei, samples were collected for electron 
microscopy analysis, immunoblots and immunofluorescence against known mitochondrial 
proteins. Of note, we decided to add all necessary cofactors (NAD+, FAD+, ADP, ATP, etc, 
see methods) in equimolar concentrations to ensure that the reactions that did not occur were 
not due to cofactor(s) limitation.  
Assessment of nuclei purity 
To assess the status of the isolated nuclei regarding possible contaminations, we 
performed electron microscopy analysis, as well as immunoblotting and immunofluorescence 
against known cytoplasmic and mitochondrial proteins. Electron microscopy showed that the 
nuclei were free of intact mitochondria, however they were surrounded by membranes the 
origin of which is not possible to be verified by electron microscopy (Figure 5). Immunoblots 
with antibodies against beta-tubulin revealed no cytoplasmic contamination, while antibodies 
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against mitochondria gave no signal for known matrix or shuttling mitochondrial proteins 
(isocitrate dehydrogenase 2, IDH2, and cytochrome c, respectively), and a positive signal for 
the mitochondrial membrane protein COXIV (Figure 5). When immunofluorescence for COXIV 
was performed, no staining of the nuclei was observed (Figure 5). These findings denoted that 
the isolated nuclei, although free of whole intact mitochondria, bear fragments of mitochondrial 
membranes. As a result, we decided to include into our 13C-labeling scheme, 13C-substrates 
that could serve as guides of a possible mitochondrial contamination. 
 
Figure 4: Experimental design of the nuclei labeling with 13C metabolic substrates. 
 
Along these lines, as a first step, we incubated nuclei with [U-13C]-pyruvate. On a 
cellular-wide context, pyruvate is converted to acetyl-CoA (pyruvate dehydrogenase complex, 
PDC activity) which subsequently condensates with oxaloacetate for the generation of citrate 
(citrate synthase, CS activity). Part of the citrate further continues in the TCA cycle for the 
production of intermediates (Figure 6). Utilizing [U-13C]-pyruvate as a substrate in the isolated 
nuclei did not result in the detection of any labelled TCA cycle intermediate. In terms of 
metabolite presence, apart from the [U-13C]-pyruvate, we only detected small amounts of 
unlabeled succinate and aspartate. The latter two metabolites were consistently detected in 
the intra-nuclear space of all isolated nuclei along with various amino acids and sugar 
compounds (i.e. glucose, fructose). In the cell lysates, the utilization of [U-13C]-pyruvate 
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resulted in labeling in expected compounds, including aspartate and succinate, denoting thus 
that the cultivation conditions were not a limiting factor for the absence of labeling in the 
isolated nuclei (appendix, Figure 30). Moreover, the absence of labeled metabolites were in 
line with expectations, since although nuclear PDC has been shown to produce acetyl-CoA 
for histone acetylation in certain mammalian cell lines30, nuclear citrate synthase (CS) 
presence and activity has been defined only for a very specific developmental stage in mice 
embryos31. As such, pyruvate carbon entry in metabolites other than acetyl-CoA is not 
expected, and the [U-13C]-pyruvate tracer served as an internal negative control regarding the 
purity of our system. Acetyl-CoA cannot be measured with GC-MS, thus we could not conclude 
whether PDC was active and the subsequent enzymes were not, or whether in our system 
this reaction did not occur too.  
 
Figure 5: Nuclei purity assessment. (a) Immunofluorescence of total cell lysates (upper panel) and nuclei (lower 
panel). Mito Red (red) stains cardiolipin, a lipid detected in the inner mitochondrial membrane. COXIV (green) is an 
inner mitochondrial membrane protein. DNA was labeled with Hoechst staining. (b) Immunoblotting for COXIV (inner 
mitochondrial membrane), cytochrome c (mitochondrial shuttling protein), isocitrate dehydrogenase 2 (IDH2, 
mitochondrial matrix protein) and beta-tubulin (cytoplasmic protein) in nucleus (N), cytoplasm (C) and total cell lysates 
(TC) samples. (c) Electron microscopy of total cell lysates (upper panel) and nuclei (lower panel). Red arrows point 
to mitochondria.  
 
[U-13C]-glutamine is a precursor of key TCA intermediates in the HeLa nucleus 
A major anaplerotic substrate of TCA is the amino acid glutamine which feeds the 
cycle predominantly at the level of alpha-ketoglutarate. Alpha-ketoglutarate is an important 
epigenetic-related metabolite, as it is a necessary co-factor for the function of specific DNA 
and histone demethylases. As such, we sought to determine whether [U-13C]-glutamine 
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supplementation could contribute in the production of alpha-ketoglutarate or any other 
metabolite in the nucleus. Incubating HeLa nuclei with [U-13C]-glutamine resulted in the 
production of labeled glutamate, succinate, fumarate and aspartate (Figure 6). Regarding 
alpha-ketoglutarate, we were not able to detect even the unlabeled form. A possible 
explanation could attributed to a very low concentration, or to its highly labile nature, as well 
as to its instability, as mentioned in studies performed in cell lysates96,97. Regarding the 
detected labeled metabolites, glutamate and aspartate labeling reached 90% and 84%, 
respectively, already after 1h of incubation, while succinate and fumarate approached 45% at 
5h. The slight reduction in the labelling percent of succinate at 5h compared to 1h, could be 
coupled to its conversion to fumarate whose labelling percent increased from 21% (1h) to 45% 
(5h) (Figure 6). It should be noted that although the labeling percent in fumarate approximated 
the one in succinate at 5h of incubation, the peak area for the labeled fumarate ion was at the 
detection limit, implying that very low amounts were generated.  
The presence of labeled glutamate is not unexpected as glutamine can non-
enzymatically convert to glutamate. Glutamate subsequently enters the TCA cycle upon 
conversion to alpha-ketoglutarate, a step that in mammalian cells is catalyzed by glutamate 
dehydrogenase (GLUD1) or by aspartate transaminase (GOT1 or GOT2) (Figure 6). GLUD1 
and GOT2 are currently considered mitochondrial enzymes both of which possess an NLS, 
albeit with no apparent nuclear staining in literature data or in Human Protein Atlas. GOT1 
resides mainly in the cytoplasm, however there are supported evidence in Human Protein 
Atlas for a nuclear presence too with unexplored function so far. Upon alpha-ketoglutarate 
formation, succinate production can derive from two possible pathways (Figure 6). The first, 
and more prevailing in cells, pathway encompasses the sequential activities of alpha-
ketoglutarate dehydrogenase complex (OGDC) and succinate-CoA ligase (SUCL) for the 
generation of succinyl-CoA and succinate, respectively. The topology of OGDC in the nuclear 
compartment has been recently discovered and was connected to a local generation of 
succinyl-CoA, the succinyl moiety of which is used for the succinylation of histones34. The 
alternate option involves the activities of alpha-ketoglutarate dependent dioxygenases 
(demethylases) which directly produce succinate from the decarboxylation of alpha-
ketoglutarate in the process of hydroxylating various substrates, including histones and 5-
methylcytosine (5mC) residues in DNA. For these demethylases, succinate can antagonize 
alpha-ketoglutarate and act as a competitive inhibitor18. Succinate will then convert to fumarate 
through a reaction that requires the catalytic activity of SDHA-SDHB heterodimer (Figure 6). 
Although in the mitochondria the heterodimer is anchored in the inner mitochondrial 
membrane through the subunits SDHC and SDHD, upon several conditions it dissociates still 
retaining its functional activity98,99. Interestingly, SDHA-SDHB presence and activity in nucleoli 
of normal and cancerous cells was first demonstrated in the early 60s35,36. Current topological 
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evidence from Human Protein Atlas support a clear localization of the catalytic subunits in the 
nucleus and nucleolus, however their role in this compartment has not been further 
investigated.  
 
Figure 6: Glutamine is a precursor of key TCA intermediates in the HeLa nucleus. Mass isotopomers analysis 
of specific TCA metabolites in the nucleus and total cell lysates after incubation with [U-13C]-glutamine, or [U-13C]-
succinate, or [U-13C]-pyruvate, for 1h or 5h. The figure also includes a schematic representation of the TCA cycle with 
the expected carbon atom (circles) transitions. Filled black, dark green and grey circles denote the 13C carbons derived 
from [U-13C]-glutamine, [U-13C]-succinate and [U-13C]-pyruvate, respectively. 12C carbons are depicted as empty 
circles. For aspartate and glutamate, instead of the full carbon backbone, the detected ions corresponded to a three 
and four fragment ion, respectively (the missing carbon is depicted as a grey circle). Dark and grey colored metabolites 
correspond to quantified and non-quantified/non-detected features in the nuclei samples, respectively. Error bars 
denote the mean ± standard error of the mean (sem) of 3 independent experiments. Abbreviations: oaa, oxaloacetate. 
Aspartate is a proteinogenic metabolite, as well as a nitrogen and carbon donor for 
the synthesis of purines and pyrimidines62,63,100,101. The presence of labeled aspartate in the 
nucleus necessitates the presence of labeled oxaloacetate, since the carbons of the latter are 
required for aspartate biosynthesis through the activity of aspartate aminotransferase (GOT 1 
or GOT2)49. To generate oxaloacetate, the most predominant pathway is through the oxidative 
route (clockwise) of TCA cycle - alpha-ketoglutarate produces succinate followed by 
conversion to fumarate, malate and eventually to oxaloacetate (Figure 6). An alternative 
pathway, operating under specific conditions, involves the reductive carboxylation of alpha-
ketoglutarate (anti-clockwise) into isocitrate and then to citrate102,103. Citrate is eventually 
cleaved by ACLY to acetyl-CoA and oxaloacetate (Figure 6). The oxidative and reductive TCA 
 Chapter I: Uncovering metabolic activities in the mammalian nucleus 
 
 
43 
 
pathways can be dissolved by the presence of specific isotopomers in the labelling patterns 
of individual metabolites96,97. This however requires the detection and quantification of ions 
that correspond to the full carbon backbone of the metabolites, which, for the case of aspartate 
was not possible owing to the detection of only a three carbon fragment and not of the whole 
four carbon backbone.  
To indirectly resolve which pathway contributes to aspartate biosynthesis, we decided 
to supplement the nuclei with [U-13C]-succinate. The presence of labeled aspartate in this case 
would imply the activity of the oxidative route, considering that alpha-ketoglutarate to succinate 
reactions can be regarded to operate only in the forward and not backward direction96. The 
[U-13C]-succinate tracer did not result in the detection and labeling of any metabolite apart 
from fumarate (Figure 6), suggesting that the fumarate to oxaloacetate axis is not taking place 
in the nucleus. The absence of labeling in aspartate indirectly connoted that the reductive 
route should then contribute to its generation. In this scenario, a metabolic tracer towards the 
end of the reductive pathway, for example citrate, would provide for the labeled aspartate 
carbons.  
[U-13C]-citrate reconstructs a citrate to succinate axis in HeLa nuclei  
As a consequence of the aforementioned results, we next aimed to assess whether 
citrate, a key metabolic intermediate laying in the intersection for the generation of two 
important epigenetic-related metabolites in cells, that of acetyl-CoA and alpha-ketoglutarate, 
could in turn contribute in the production of aspartate or other TCA-related intermediates in 
the nucleus. Feeding HeLa nuclei with [U-13C]-citrate as a labeling substrate resulted in the 
detection and labeling of a single metabolite, that of succinate, 80% of which was labelled 
after 5h of incubation (Figure 7). In total cell lysates, all expected metabolites were detected, 
including the ones downstream of succinate (i.e. fumarate, malate, aspartate etc.), along with 
the respective isotopomers (Figure 7).  
In mammalian cells, the predominant pathway for succinate generation from citrate 
involves as a first step the citrate conversion to isocitrate by aconitase (ACO1 or ACO2), and 
then to alpha-ketoglutarate by isocitrate dehydrogenase (IDH1, IDH2 or IDH3) (Figure 7). Both 
ACO2 and IDH3 feature a metabolic activity in the nucleus connected to alpha-ketoglutarate 
production, albeit such an activity was linked only to mouse embryonic development and found 
absent in later stages31. Interestingly, ACO2 was identified in yeast nuclei with uncharacterized 
function so far33, while topological evidence from mammalian cells reveal cell line-specific 
nuclear localization as it is observed in nuclei of U-251 MG (glioblastoma) cells. IDH3G (one 
of the subunits of IDH3), and IDH1 to lesser extent, show a nuclear localization in multiple 
mammalian cell lines. Finally, as discussed earlier, our sequence analysis identified NLS for 
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both ACO2 and IDH3G enzymes (Figure 3). To verify whether succinate production in the 
nucleus involved indeed the activity of aconitase, we treated isolated nuclei with the aconitase 
inhibitor fluorocitrate in the presence of [U-13C]-citrate. This resulted in a two-fold reduction in 
the labeling of succinate (40%) supporting such an activity to be present in the nucleus of 
HeLa cells (Figure 7). 
Regarding our hypothesis for aspartate generation through the reductive route, the 
[U-13C]-citrate tracer did not confirm it as we did not observe any labeled aspartate (Figure 7). 
Retrospectively, we hypothesized that this could partially be attributed to the concentration of 
citrate used in this study - citrate is a known metal chelator and as such inhibits the activities 
of many enzymes. In addition, citrate is a known allosteric inhibitor for several metabolic 
enzymes, including SDH104. The latter could explain why the [U-13C]-citrate tracer did not reach 
a labeled fumarate in the nucleus (Figure 7) contrary to the [U-13C]-glutamine (Figure 6). 
Indeed, when total cell lysates were incubated with a concentration of [U-13C]-citrate tracer 
that contributed in 80% of succinate being labeled (approximating thus the percentage of 
labeled succinate found in the nucleus), fumarate was unlabeled indicating an inhibition of 
SDH activity (Figure 7). In the same experiment, we observed labeled malate pointing to its 
generation from oxaloacetate which derived from citrate through the activity of ACLY (Figure 
7). Although oxaloacetate contributed to malate, there was no labeling in aspartate denoting 
that GOT enzyme did not operate under these conditions and was inhibited by citrate (Figure 
7c). Overall, the results in total lysates could partially explain our hypothesis regarding 
possible reasons why reductive aspartate synthesis was absent in the nucleus after [U-13C]-
citrate supplementation, however, further experimental repetition with lower citrate 
concentration levels in nuclei is required to validate its actual presence and contribution in the 
production of aspartate.  
Collectively, the labeling data revealed that a functional metabolic pathway operate in 
the nucleus, a pathway that is made of parts of the TCA cycle. Several lines of evidence 
offered by internal negative control labeling results supported the purity of our system, for 
instance the absence of contribution in metabolic nuclear pools after [U-13C]-pyruvate 
supplementation, or the absence of labeling of specific TCA metabolites in the nucleus (i.e. 
malate) contrary to total cell lysates. In addition, the design of our experimental scheme 
involved the washing of the nuclei from the extranuclear medium prior to collection and 
metabolite extraction, denoting that the labeling results reflected intranuclear labeled pools. 
Our results thus indicated that [U-13C]-glutamine, [U-13C]-citrate and [U-13C]-succinate are 
actively converted to metabolites with previously recognized roles in epigenetic modifications, 
and as such, they complement existing studies by further reconstructing an entire axis up to 
the formation of fumarate being active in the HeLa nucleus.   
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Figure 7: [U-13C]-citrate supplementation reconstructs a citrate to succinate axis actively present in HeLa 
nuclei. (a) Schematic representation of the TCA cycle along with the carbon atom (circles) transitions of specific 
metabolic intermediates obtained after supplementation and 5h incubation of isolated nuclei with [U-13C]-citrate. Filled 
black circles denote the 13C carbons derived from [U-13C]-citrate. 12C carbons are depicted as empty circles. Dark and 
grey colored metabolites correspond to quantified and non-quantified/non-detected features in the nuclei samples, 
respectively. Abbreviations: oaa, oxaloacetate. (b) Succinate biosynthesis in the nucleus involves the activity of 
aconitase as a first enzymatic step. After [U-13C]-citrate supplementation, ~80% of succinate was labeled (M4 
isotopomer). Incubation with an aconitase inhibitor (fluorocitrate) in the presence of [U-13C]-citrate resulted in a two-
fold reduction of the labeled succinate (M4 isotopomer). The graph corresponds to the mass isotopomers analysis of 
succinate (mean ± standard error of the mean (sem) of 3 independent experiments). (c) Mass isotopomers analysis 
of TCA intermediates after supplementing total cell lysates with 2µM [U-13C]-citrate – all expected metabolites and 
isotopomers are detected. (d) Mass isotopomers analysis of TCA intermediates after supplementing total cell lysates 
with 10µM [U-13C]-citrate results in inhibition of several enzymatic steps as depicted by the absence of specific labeled 
metabolites. Abbreviations: pyr, pyruvate; lac, lactate; cit, citrate; suc, succinate; glu, glutamate; fum, fumarate; mal, 
malate; asp, aspartate. In (b), (c) and (d), M0 (unlabelled) to Mn (labelled in n carbons) indicate the different mass 
isotopomers. 
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Towards the identification of a nuclear niche using proximity 
biotinylation mass spectrometry 
To further investigate the aforementioned subnetwork of metabolic enzymes, we 
decided to explore their protein-protein interaction (PPI) network. While these enzymes have 
been studied with a wide range of biochemical methods, very few have been used as baits in 
interaction networks and often are confined to a mitochondrial metabolic perspective. A 
systematic characterization of their PPI could point to additional localizations and 
functionalities. To this end, we used proximity labeling mass spectrometry based on the BioID 
system105. In this method, the protein of interest is fused to a promiscuous prokaryotic biotin 
ligase which, in the presence of excess biotin, catalyzes the biotinylation of lysine residues in 
the interacting and neighboring proteins. The biotinylated proteins are subsequently affinity-
purified with streptavidin beads and identified by mass spectrometry. The advantage of this 
method that prompted us to incorporate it in our experimental scheme is that it allows for 
mapping of the protein-protein interactome in living cells. Because of this, and owing to the 
nature of the modification which remains present even after harsh lysis conditions, weak and 
transient interactions are also able to be captured. Since the biotin ligase allows the 
biotinylation of any protein within a 10-50 nm radius106,107, the identified interactors are not 
constrained to only direct but also to proximal ones, allowing thus to probe the molecular 
environment and identify additional subcellular neighborhoods.  In this way, the BioID can offer 
higher sensitivity in capturing more dynamic or smaller niches especially when the relative 
distribution of the examined protein is enriched for a specific compartment which could mask 
the detection of the protein elsewhere when conventional methods are used (i.e fluorescence 
microscopy).  
Our targets included aconitase 2 (ACO2), isocitrate dehydrogenase 3 (IDH3) and the 
2-oxolglutarate dehydrogenase complex (OGDC) covering the citrate to succinly-CoA 
pathway (Figure 8). IDH3 has three distinct subunits, IDH3A, IDH3B and IDH3G, and is 
organized as a heterotetramer composed of the heterodimers IDH3A-IDH3B and IDH3A-
IDH3G108. Out of the three subunits, the IDH3B and IDH3G contain a nuclear localization 
signal and we chose to tag IDH3G owing to a more visible nuclear staining in the Human 
Protein Atlas database94. OGDC is comprised of three subunits, the 2-oxoglutarate 
dehydrogenase (OGDH), the dihydrolipoamide succinyl-transferase (DLST) and the 
dihydrolipoamide dehydrogenase (DLD). Since the OGDH subunit contains a nuclear 
localization signal we decided to tag this one as a representative of the whole complex. As a 
negative control sample, we used the isocitrate dehydrogenase 2 (IDH2) which is a purely 
mitochondrial enzyme. In the study we included as additional control samples, the pyruvate 
dehydrogenase B (PDHB), a subunit of the PDC complex which has been shown that although 
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it mainly localizes in the mitochondria it can shuttle to the nucleus as well30, and isocitrate 
dehydrogenase 1 (IDH1) which has a predominantly cytoplasmic localization but a small 
fraction is detected in the nucleus too94.  
The six aforementioned enzymes were fused to a smaller version of biotin ligase 
(BioID2) which has been shown to minimize improper subcellular localization of the 
engineered proteins106. In addition to BioID2, FLAG tag was also included in the sequence. 
For all the enzymes, the BioID2-FLAG was introduced in the C-terminus, while for PDHB, 
IDH2 and OGDH, N-terminally fused versions were created as well. Each engineered enzyme 
was stably integrated in the tetracycline inducible Flp-In T-Rex HeLa cell system. The 
induction of the protein expression was facilitated by addition of tetracycline for 24hr, followed 
by biotin supplementation for protein biotinylation for another 24hr. The labeling and affinity 
purification of the biotinylated proteins was performed for four biological replicates per case, 
including wild type parental cells, and the mass spectrometry was performed with 10-plex 
tandem mass tag (TMT) labeling (Figure 8).  
 
Figure 8: Proximity biotinylation mass spectrometry based on the BioID method. (a) Selected targets are 
depicted with red color. For the complexes PDC, IDH3 and OGDC, the selected subunits was based on the presence 
of NLS in their protein sequences. (b) Graphical abstract of the experimental scheme. 
To create a first rough network of the proximal interactome of each enzyme, each 
stable cell line was compared to wild-type parental HeLa cells. The significant results were 
further refined by excluding proteins that have been identified in negative control HeLa-BioID 
samples deposited in the CRAPome database109. Pairwise pearson correlation analysis 
between the rough proximal networks revealed two main clusters (Figure 9a). The C-tagged 
versions of the mitochondrial enzymes were positively correlated with each other, forming one 
of the two main clusters, and negatively correlated with the cytoplasmic IDH1. Consistent with 
the expectations, Gene Ontology (GO) analysis revealed the mitochondrion as the top 
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enriched cellular component term (appendix, Table 5). However, for the three enzymes that 
were analyzed as both C- and N-terminally fused versions, the correlation between the two 
termini was negative, with the N-fused ones grouping with IDH1, forming all together the 
second main cluster (Figure 9a). Here, gene ontology (GO) analysis revealed as top cellular 
component enrichments the cytoplasm and cytoskeleton (Supplementary section, Table 5). 
Further subcellular annotation of the hits showed that no purely mitochondrial proteins were 
detected in the N-fused versions. In addition, the known interaction partners of the OGDH and 
PDHB were only captured in the C-tagged fusions. While the absence of the known partners 
could be associated with the sampling of different interactors by the two termini, altogether the 
observations pointed to inability of the N-fused enzymes to access the mitochondria. This is 
possibly attributed to inaccessibility of the mitochondrial import signal that most mitochondrial 
proteins carry in their N-terminus110. As a result, we decided to exclude the N-fused versions 
from further analysis.  
The aforementioned results depict a first rough representation of the proximal 
interactome. To further refine them, we decided to use one of the N-fusions, namely N-fused 
IDH2, as an additional negative control sample which would account for further eliminating 
unspecific proteins as a result of the exogenous expression of the biotin ligase in the cells. 
With the addition of this control, the final number of significant proximal interactors ranged 
from 108 (C-tagged OGDH) to 271 (C-tagged IDH2) (Figure 9b). An overview of pearson 
correlation coefficients can be viewed in Supplementary Figure 2. ACO2 and IDH2 had the 
highest correlation (R2 = 0.95), consistent with the fact that they share an immediate 
neighborhood participating in the catalysis of sequential reactions in the mitochondrion. 
Together with PDHB, ACO2 and IDH2 formed a highly correlated cluster (core), sharing 239 
proximal interactors, followed by IDH3G which shared 139 proximal interactors with the above 
core (139 out of the 157 total interactors, 88% overlap) (Figure 9b). OGDH shared the least 
number of proximal interactors with the core (83 out of 108, 76% overlap), and more with 
IDH3G (89 out of 108, 82% overlap) (Figure 9b).  
While the vast majority of the proximal interactors represented the primary molecular 
neighborhood of the enzymes (Figure 9d), we were able to resolve smaller clusters with 
distinct biological processes and probable subcellular niches associated with specific 
enzymes. This is instantiated in Figure 9d with clusters 2, 4 and 5. Of particular interest, cluster 
4 represents a highly enriched group in OGDH and IDH3G enzymes, followed by mediocre 
enrichment in ACO2 (out of the total number of proteins detected in the cluster, 11% were 
statistically significant in ACO2) but largely excluded from IDH2 and PDHB. Gene ontology 
analysis revealed as top biological process the rRNA metabolic modifications (p value, 3.3x10-
6), and as subcellular components the pre-ribosome (p value, 4.3x10-7) and the nucleolus (p  
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Figure 9: Exploration of the proximal interactomes of ACO2, OGDH and IDH3G. (a) and (b), Pairwise Pearson 
correlation analysis and Venn diagram of the significant biotinylated proteins detected in each engineered cell line, 
respectively. An asterisk at the beginning and the end of the protein name is representative of the C- and N-fusion of 
the biotin ligase-FLAG, respectively. (c) Pairwise comparisons of the significant proximal interactors (log2 fold 
changes when compared to wild type HeLa) between the C-fused i) ACO2 and IDH2, ii) IDH3G and IDH2, iii) OGDH 
and IDH2. Red and green color indicates the proximal interactors that are significantly enriched in ACO2, IDH3G or 
OGDH when compared to IDH2 cell line, and in reverse, respectively. (d) k-means clustering of the significant proximal 
interactors revealed five major clusters (left panel) that were further characterized by Gene Ontology (GO) enrichment 
analysis for the terms “Biological Process”, “Molecular Function” and “Cellular Component” (right panel) using the 
g:Profiler112,113. Color gradient for the k-means clustering corresponds to log2 fold changes of each engineered cell 
line compared to wild type HeLa.  
 
value, 8.1x10-6) which is connected to the transcription of ribosomal genes and rRNA 
processing and assembly with ribosomal proteins111. Consistent with the aforementioned, the 
cluster was also enriched for RNA binding molecular function (p value, 5.1x10-3). Cluster 5, 
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presented in IDH3G and moderately in IDH1, was enriched for isocitrate dehydrogenase 
activity, as expected. Interestingly, we also detected proteins of a complex with histone 
acetyltransferase, as well as DNA helicase activity (Figure 9d).  
To have a better overlook of the topological distribution of the identified proximal 
proteins, we used subcellular localization information derived from Uniprot, Human Protein 
Atlas94 and Compartment114 databases (Figure 10). OGDH had the highest fraction of proteins 
characterized as of “purely nuclear” topology (14.9%, 16 proteins), followed by IDH1 (9.8%, 
22 proteins) and IDH3G (5.2%, 8 proteins). The same topological category in ACO2 involved 
five proteins (1.9%). However, two of them (SPRYD4 and TRMT11 - the first of unknown 
function and the latter connected to tRNA methyltransferase activity) were also detected in the 
negative control IDH2, as well as in PDHB, being the only “purely nuclear” proteins in these 
samples (corresponding to 0.8%). In a recently published BioID study107, these two proteins 
were present amongst the proximal interactors of four mitochondrial matrix proteins (CH60, 
TR61B, PDK1 and MRM1) and absent from the interactome of any other non-mitochondrial 
protein, corroborating thus that although they are annotated as purely nuclear in the 
databases, they are associated with the mitochondria. We further analyzed the results of this 
study to get an estimate of their “purely nuclear” topological distribution and compare it to ours. 
The proximal interactomes of CH60 and PDK1 had a 0.8% characterized as of purely nuclear 
topology involving the same two proteins described above (TRMT11, SPRYD4). For TR61B 
we found one additional nuclear protein (3 proteins in total, 1.3%) and for MRM1 three more 
(5 proteins in total, 2%). The fact that in at least one of these mitochondrial protein there is still 
a 2% of nuclear proteins confounded the significance of our ACO2 “purely nuclear” results. 
For AIFM1, which is a mostly mitochondrial matrix protein but also detected in the nucleus and 
cytoplasm, there was a 5.2% of purely nuclear features (9 proteins in total), similar to the 
percentage of our IDH3G.  
Taken together, the aforementioned indicated the correct localization of the C-tagged 
enzymes to their primary mitochondrial compartment (or cytoplasmic for the case of IDH1), 
but also revealed a fraction of proteins connected exclusively to the nucleus for the cases of 
OGDH, IDH3G and IDH1. For ACO2, we identified three “purely nuclear” proteins, however, 
owing to the small percentage, the nuclear topology for ACO2 itself remained ambiguous. 
Finally, although PDHB has been described in the literature as having a nuclear topology30 in 
addition to the mitochondrial one, we were not able to identify any purely nuclear protein in 
our dataset.  
The high number of proximal interactors detected with the above analysis is consistent 
with the fact that the BioID method captures the immediate environment of the tagged protein. 
In order to identify more preferential and more specific interactors even within the same  
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Figure 10: Subcellular distribution of the proximal interactors. The topological annotation was based on Uniprot, 
Human Protein Atlas94,95 and Compartments114 databases. The proximal interactors of CH60, PDK1, TR61B, MRM1 
and AIFM1 were obtained from the study of Liu et al107 and refer to mitochondrial proteins fused to a larger version of 
biotin ligase stably integrated in Flp-In T-REx 293 cells. 
environment, we decided to compare each enzyme to another fellow, in addition to the wild 
type parental HeLa cells and the N-fused IDH2. This way for example, ACO2 was compared 
to the C-fused IDH2 or C-fused PDHB, to parental HeLa and N-fused IDH2, and the union of 
the significant interactors was taken into consideration. The number of significant proximal 
interactors per enzyme was now significantly reduced – for instance, for the case of ACO2 
from the initial 267 proximal interactors, 17 were now included in the final list (Figure 11a). A 
list of all higher specificity interactors is provided in appendix, in Table 6. This analysis allowed 
for more specific features to appear. For instance, while IDH3A and IDH3B, known interactors 
of IDH2 and partners of IDH3G, were previously included in the proximal interactomes of all 
mitochondrial enzymes as part of the shared immediate neighborhood, now were highlighted 
for the cases of IDH2 and IDH3G only. With this analysis, the subcellular topological 
distribution highlighted further the purely nuclear fraction present in OGDH, IDH3G, IDH1 and 
now more clearly for the case of ACO2 (Figure 11b). Regarding ACO2, out of the 17 identified 
proximal interactors 3 were nuclear proteins, in contrast to the zero of the negative control 
IDH2. The respective proteins were the RBMX, HMGA1 and TOP2B - these were also 
detected amongst the significant interactors of OGDH and IDH3G but not of IDH1 (Figure 11a 
and 11d). All three proteins have been connected to chromatin binding and remodeling115–117, 
while RBMX contains an RNA-binding domain too and has been involved in pre-mRNA 
processing118. Interestingly, both TOP2B and HMGA1 have been associated to development, 
cellular differentiation and malignancy119–121. As already shown before, OGDH and IDH3G had 
the highest percentage of nuclear proteins, sharing many overlapping proximal interactors 
ranging from 53% to 78%, respectively, which was hence reflected into many shared enriched 
GO terms too. For both enzymes, for the nuclear fraction, the most enriched biological feature  
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Figure 11: Proximity biotinylation mass spectrometry reveals a potential nuclear niche for ACO2, OGDH and 
IDH3G coupled to histones, chromatin binding and RNA modifications. (a) and (b), Venn diagram and 
topological distribution of the higher specificity proximal interactors, respectively. For the topological annotation see 
details of Figure 10. For a detailed list of the higher specificity proximal interactors refer to supplementary material, 
Table 5. (c) GO Biological Process Network based on the higher specificity proximal interactors of the C-fused IDH3G 
and OGDH. Each node represents a GO enrichment “Biological Process” term and each group of nodes is described 
by a representative term (bold letters). The size of the node corresponds to the significance level (Benjamin-Hochberg 
adjusted p values). The color and color gradient indicates the specificity of the GO term for each engineered cell. GO 
terms equally enriched in both cell lines are colored grey. GO terms uniquely present in a cell line are marked with a 
black-lined circle. The GO enrichment analysis was performed with ClueGO122 and visualized with Cytoscape123. (d) 
Dotplot representation of selected proximity interactors. Histones and rRNA metabolic process related proteins are 
highlighted. Node color gradient represents the log2 fold change of the protein in each engineered cell line compared 
to wild type HeLa. The size of the node indicates the relative abundance of the above log2 fold changes amongst the 
different engineered cells. The color of the line around the node is indicative of the significance (Benjamin-Hochberg 
adjusted p values). Dotplot was generated using the ProHits Visualization web-tool124. 
was the RNA processing (Figure 11c), albeit the enrichment was 2-fold higher for the case of 
OGDH. Out of the shared enriched GO terms, while the mRNA metabolic process presented 
equal enrichment for both enzymes, the terms that drove the higher “RNA processing” 
enrichment in OGDH were attributed to ncRNA metabolic processes and more specifically to 
those of rRNA and tRNA. Finally, we additionally identified two processes that were rather 
specific to each enzyme and absent from the other. Both processes were connected to histone 
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modifications, which, for the case of OGDH was histone succinylation, and for IDH3G histone 
acetylation (Figure 11c). While the first one was connected to the activity of the enzyme which 
produces succinyl-CoA that can be used for the succinylation of histones and generally of 
other proteins too, the latter was attributed to the activities of proteins present in the proximal 
interactome of IDH3G, namely the RUVBL1 and RUVBL2. Both are components of the NuA4 
histone acetyltransferase complex involved in the acetylation of histones H4 and H2A125.  
 
Figure 12: Immunofluorescence microscopy of the engineered cell lines expressing the protein of interest 
fused to biotin ligase 2. The following stable cell lines are depicted: ACO2*, IDH2*, IDH3G* and IDH1*. Each image 
has four panels corresponding to DNA labeled with Hoechst dye (blue), anti-flag (red) (for IDH1* and IDH2*) or anti-
native protein (red) (anti-ACO2 for ACO2*, anti-IDH3G for IDH3G*), biotinylated proteins labelled with Streptavidin-
Alexa 488 (green) and merged. An asterisk at the beginning or the end of the protein name denotes the fusion of 
biotin ligase at the N-terminus or C-terminus, respectively.  
 
As a final step, we aimed to monitor the localization of the engineered enzymes and 
the biotinylated proteins using immunofluorescence microscopy based on anti-FLAG and 
streptavidin-staining, respectively (Figure 12 and 13). Anti-FLAG did not give an 
immunofluorescence signal, contrary to immunoblotting results, and hence we utilized 
antibodies targeting the endogenous proteins. Possible explanations for the lack of signal are 
 Chapter I: Uncovering metabolic activities in the mammalian nucleus 
 
 
54 
 
the general low expression of the engineered enzymes, and/or the inaccessibility of the site 
when the whole complexes are formed for the cases of OGDH and IDH3G. For ACO2 (Figure 
12) and OGDH (Figure 13), both the engineered/endogenous enzymes and the biotinylated 
proteins were observed predominantly in the mitochondria.  
 
Figure 13: Immunofluorescence microscopy of the engineered cell lines expressing the protein of interest 
fused to biotin ligase 2. The following cell lines are depicted: wild type HeLa, PDHB*, OGDH* and *OGDH. Each 
image has four panels corresponding to DNA labeled with Hoechst dye (blue), anti-flag (red) (for PDHB* and HeLa) 
or anti-native (red) (anti-OGDH for OGDH* and *OGDH), biotinylated proteins labelled with Streptavidin-Alexa 488 
(green) and merged. An asterisk at the beginning or the end of the protein name denotes the fusion of biotin ligase at 
the N-terminus or C-terminus, respectively.  
 
Although the subcellular annotations of the proximal proteins included a fraction 
characterized as of purely nuclear topology, we were not able to quantify a detectable signal 
in the nuclear compartment. We speculate that this is likely due to the uneven subcellular 
distribution of the enzymes with a primarily localization in the mitochondria and a relative small 
proportion interacting with nuclear proteins as shown by the mass spectrometry results. 
Regarding IDH3G, for the enzyme itself we detected a very clear presence in the nucleolus, 
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while the biotinylated proteins displayed a more diffused pattern throughout the nucleus and 
mitochondria (Figure 12). Finally, IDH1 proximal biotinylated partners showed a mainly 
cytoplasmic distribution (Figure 13), while the negative control IDH2 and PDHB appeared in 
the mitochondria (Figure 12 and 13).  
Summary and Outlook 
Collectively, our [U-13C]-labeling data provided strong and direct evidence that a 
functional metabolic pathway representing part of the TCA cycle operates in the HeLa nucleus. 
While existent studies have provided so far the nuclear activity of specific enzymes under 
specific contexts, we identified citrate and glutamine as two important feeding points in the 
nucleus reconstructing an entire active pathway supplementing intermediates having key roles 
in epigenetic modifications. For instance, alpha-ketoglutarate is a necessary cofactor for a 
specific class of demethylases, succinyl-CoA is the succinyl-donor for histones succinylation, 
while other downstream metabolites like succinate and fumarate act as demethylase 
inhibitors. A nuclear generation of aspartate could potential be attributed to its requirement for 
purine and pyrimidine synthesis, being close to known nucleotide-related enzymes, like CAD, 
whose nuclear presence increases during S phase when the demands for nucleotides are 
maximal126,127. The metabolic pathway was further supported by the presence of the respective 
enzymes in literature available nuclear proteomics datasets, as well as by the identified NLS 
in their protein sequences. Although with the current study we cannot exclude the nuclear 
topology of these enzymes owing to distinct, moonlighting activities, and hence the generation 
of these metabolites as a lateral effect, the apparent connection of these metabolites to 
histone, DNA or RNA modification processes couples their nuclear biosynthesis to a more 
efficient architecture by being in close proximity to sites of need. 
Proximity labelling mass spectrometry identified a nuclear niche for OGDH and 
IDH3G, and potentially also for ACO2. For ACO2, although the number of nuclear interactors 
was limited to three, these were included amongst the higher specificity and preferential 
proximal interactome. In addition, several nuclear proteins detected in OGDH and IDH3G had 
a minor presence in ACO2, albeit not significant, which could point to a condition-specific 
enrichment of ACO2 in the nuclear compartment (Figure 11d). Further exploration of their 
proximal interactome revealed projections to chromatin, histones and RNA metabolic 
processes. A nuclear presence could be connected to a local generation of succinyl-CoA by 
OGDH further used for the succinylation of histones. While our work was in progress, one 
additional study was published showing that KAT2A acetyltransferase interacts with OGDH 
and utilizes the generated succinyl-CoA for the succinylation of histone H334. Although in our 
dataset we did not recapitulate the OGDH-KAT2A-H3 axis, we identified connections to 
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histone H4 and the histone H2A variants H2AFZ or H2AFV and H2AFY, denoting a similar 
role (Figure 11d). The same study quantified that only 1–1.6% of total OGDH, DLST, and DLD 
is localized in the nucleus, further supporting the absence of a clear nuclear staining in our 
immunofluorescence results too. Finally, the presented enrichment in RNA processes is a 
more complex and intriguing one. This relationship could be attributed to the fact that several 
metabolic enzymes, including TCA cycle enzymes, have been characterized as RNA binding 
proteins, with this characteristic being currently of unknown biological role128–130. Apart from or 
conjointly to this, a connection might be drawn to RNA modifications per se, where, similarly 
to DNA and histones, specific metabolites are utilized as substrates or co-factors for their 
formation. Although our investigated pathway did not include enzymes that generate 
metabolites directly employed for these RNA modifications (i.e. SAM), it was coupled to alpha-
ketoglutarate production, a necessary co-factor for specific classes of DNA and histone 
demethylases, few of which have been lately discovered for mRNA and tRNA, though not 
rRNA yet20. All the aforementioned provide just the basis of some initial functionally relevant 
connotations which however render of advanced systematic characterization and further 
validation. Overall, the proximal interaction dataset provides a resource for furthering the 
exploration and organize follow up experiments laying at the conjunction of metabolism and 
its gene expression regulation pleiotropic roles.   
 
Figure 14: Proposed nuclear metabolic network and relevant functions. 
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Chapter II: Metabolic particularities of minimal residual 
disease in breast cancer 
Metabolic reprogramming is fundamental to the robustness of cancer cells. These 
enable them to adapt and support their growth and proliferation in the face of hindering 
environments and genetic mutations. Although these altered metabolic features have been 
extensively studied in tumors, much less is known about the metabolic states that characterize 
residual, dormant cancer cells which escape treatment and contribute to cancer recurrence 
and therapy resistance (known as minimal residual disease). Understanding the metabolic 
pathophysiology of this population is important both for their effective diagnosis and for 
identifying pathways that could be limiting for their growth. A recent study from Havas and 
colleagues131, showed that regressed mouse breast cancer cells, although phenotypically 
similar to their normal counterparts, possessed a distinctive transcriptional profile which 
pointed to metabolic alterations. Following this lead, the current thesis contributed to the 
comprehensive characterization of the metabolic physiology of these residual cells. To achieve 
this, metabolomics analyses were employed to complement transcriptomics and phenotypic 
data in three-dimensional cell cultures of primary epithelial cells isolated from mammary 
glands of the breast cancer mouse model. The identified key metabolic idiosyncrasies were 
further verified in the in vivo mouse model.   
Tumor and residual cells exhibit divergent response at the 
transcriptomic and metabolic level  
Considering the inherent challenges involved in the recognition and isolation of 
residual, dormant cancer cells in vivo, animal models correlative to human cancers offer an 
advantageous alternative system. The system employed in the current study was based on a 
mouse model of breast cancer, wherein the cancer formation can be initiated with the 
doxycycline-inducible and mammary-specific overexpression of two oncogenes, Myc and 
Neu. Myc oncogene is mutated human Myc, and Neu is coming from rat and is equivalent of 
the human epidermal growth factor receptor 2 (HER2). Increased MYC and HER2 expression 
is frequently observed in breast cancers, with HER2 overexpression occurring in 
approximately 25-30% of the known cases132. Once oncogene overexpression is seized (i.e. 
upon doxycycline withdrawal), tumor regresses and mammary glands are phenotypically 
similar to their normal counterparts. However, spontaneous tumors may reoccur in these mice, 
representing thus a system that simulates the kinetics of tumor progression, regression and 
relapse. This in vivo cancer kinetics can be recapitulated in vitro, in three-dimensional cell 
cultures of primary epithelial cells isolated from the mammary glands of the breast cancer 
mouse model131. When the cells are seeded in a basement membrane extract (Matrigel) mixed 
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with collagen are able to form three-dimensional structures that resemble the respective ones 
found in vivo and which are named acini. The breast acini are units built from single layer of 
polarized epithelial cells localized around the lumen of the duct and surrounded by an outer 
layer of myoepithelial cells and the basement membrane. When doxycycline is added to the 
growth medium, oncogene overexpression is induced resulting in the formation of tumors 
represented as filled acini. Upon doxycycline withdrawal, the majority of the cells undergo 
apoptosis, which results in the lumen clearing out and structures regressing and organizing 
back to a single-layered rim of polarized epithelial cells. These surviving cells represent the 
cancer residual population (Figure 15).  
 
Figure 15: Residual cells are phenotypically similar to their normal counterparts. Upper panel: ITGA6 (red), 
ZO-1 (green), GM-130 (magenta). Lower panel: human MYC oncogene (green); E-cadherin (CDH1, in red) as a 
counterstain. From left to right: normal, tumor and residual structures. Scale bar: 50 µm. (figure adapted from adapted 
from Ksenija Radić Shechter, PhD thesis). 
To examine the cancer residual population, the three-dimensional cell cultures were 
collected for immunofluorescence, RNA-sequencing, lipidomics and metabolomics in the 
following states: a) cells where oncogenes overexpression was absent (hereafter denoted as 
normal), b) cells treated with doxycycline for five days and thus overexpressing the oncogenes 
(hereafter denoted as tumors), and c) cells treated with doxycycline for five days and 
overexpressing the oncogenes, followed by doxycycline withdrawal for seven days and thus 
absence of oncogenes overexpression (hereafter denoted as regressed cells). For the 
analysis at the metabolic level, apart from the intracellular samples, extracellular spent growth 
medium was also collected prior to cell harvesting, corresponding to the extracellular 
metabolome of the last 24h of the cell cultures. For the metabolomics analyses, two differential 
methods were utilized. Untargeted analysis was performed using direct injection in a hybrid 
quadrupole-orbitrap mass spectrometer (Q Exactive MS)133. For targeted analysis, Gas 
Chapter II: Characterizing the metabolic particularities of minimal residual breast cancer cells 
  
61 
 
Chromatography - Mass Spectrometry (triple quadrupole) (GC-MS) was utilized covering 
central carbon metabolic pathways. For the metabolomics analyses, one additional control 
was included where non-inducible wild type cells were treated with doxycycline (hereafter 
denoted as wild type) to account for any potential metabolic effects attributed solely to the 
doxycycline treatment.  
 
Figure 16: Tumor and residual cells exhibit divergent response at the transcriptional and metabolic level. 
Principle component analysis graphs of the transcriptomics, lipidomics and metabolomics (intracellular and 
extracellular) profiles for the control (never induced and wild type), tumor and residual populations. Eclipses represent 
the confidence interval of a multivariate normal distribution (confidence intervals 0.95).  
The immunofluorescence imaging highlighted the phenotypic similarity among the 
normal and regressed cells, and verified the absence of the MYC oncoprotein in these two 
states compared to the highly increased levels in tumor cells (Figure 15) (Ksenija Radić 
Shechter Shechter, PhD thesis). The expected expression levels of both oncogenes, MYC 
and HER2, were additionally confirmed at the transcript level for all three states (Ksenija Radić 
Shechter Shechter and Katharina Zirngibl, PhD theses). The RNA-sequencing derived 
transcriptome profiles exhibited a clear separation between the three states, with the 
regressed cells being closer to the normal than to the tumor, as indicated by the principle 
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component analysis (PCA) graph (Figure 16). This result further confirmed the initial study 
from Havas and colleagues, where transcriptome differences based on microarray analysis 
were also observed for all three states131. Notably, despite the transcriptome profile of the 
regressed cells being more close to the normal population, the distances at the metabolic level 
amongst the three states exhibited a differential pattern. As defined by both intracellular 
untargeted and targeted metabolomics analyses, the metabolic profile of the regressed cells 
was more similar to the tumorous population than to their normal counterparts. This is reflected 
in the principle component analysis of the intracellular targeted metabolomics results (Figure 
16), based on the quantification of 53 polar metabolites covering central carbon metabolism, 
as well as in the hierarchical clustering of the untargeted metabolomics results based on 2832 
detected ions (Figure 17). A similar pattern was also observed at the extracellular targeted 
metabolic profiles (based on 36 quantified metabolites), albeit with a more clear separation of 
the residual from the tumor state (Figure 16), as well as at the level of lipids (Figure 16). To 
assess whether the distances between the three states at the transcriptomic level could 
resemble the ones present at the metabolic level if solely the gene expression of metabolic 
enzymes is included, principle component analysis of the RNA-sequencing data was 
performed excluding all non-metabolic genes. Despite this, the principle component analysis 
did not result in changes in the transcriptional distances (Ksenija Radić Shechter and 
Katharina Zirngibl, PhD theses), suggesting that the higher metabolic similarity between the 
residual and tumor cells points towards the existence of a tumorous metabolic memory 
preserved in the residual population.  
 
Figure 17: The metabolic profile of residual cells is more similar to the tumor than the control state. 
Hierarchical clustering of control (never induced and wild type), tumor and residual populations based on the 
untargeted metabolomics method for intracellular samples (unsupervised hierarchical using the Manhattan distance) 
(figure adapted from adapted from Katharina Zirngibl and Ksenija Radić Shechter, PhD theses). 
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The metabolic alterations of the residual population are mnemonic of the 
tumorous state 
To gain a deeper insight of the metabolic physiology that characterizes the residual 
as well as the tumor cells, we next examined the intracellular and extracellular metabolic 
changes identified in these two populations when compared to the normal state. The 
untargeted metabolomics analysis provided preliminary information regarding altered 
metabolic pathways, however the multiple annotations per ion renders the identification of 
metabolites challenging. For this reason, we utilized the targeted metabolomics analyses 
owing to the precise identification of the detected metabolites which covered multiple central 
carbon metabolic pathways, including glycolysis along with branching pathways, TCA cycle, 
glutamine metabolism, urea cycle, amino acids and several free fatty acids. An overview of 
the quantified metabolites in intracellular samples is provided in Figure 18. The hierarchical 
clustering based on the metabolite concentration pools revealed once again the higher 
similarity between the residual and tumor cells, as well as that doxycycline treatment did not 
induce overall changes in the metabolic physiology of the control cells. When compared to the 
control state, the tumor population exhibited changes in the concentration of several 
metabolites connected to metabolic pathways frequently deregulated in cancers characterized 
by overexpression of the oncoproteins MYC and HER2. Notably, the residual population, 
despite the absence of the overexpression of the two oncogenes, retained similar changes in 
their metabolic profiles, with differential magnitude in different pathways. An overview of all 
significant alterations in the intracellular and extracellular samples is provided in the appendix 
section, Figure 32. The significantly detected changes are discussed below per pathway, in 
parallel for the tumor and regressed populations.  
Of the most prominent metabolic alterations was the glucose intracellular and 
extracellular pool sizes which were largely decreased in both tumor and residual cells when 
compared to the normal state (Figures 19-21). Pyruvate, the end glycolytic metabolite which 
can be converted to lactate, alanine or acetyl-CoA, was also reduced intracellularly and 
extracellularly both in tumor and regressed cells. On the other hand, lactate and alanine 
extracellular pools were significantly increased in both states. The reduced glucose 
concentration levels combined with the significantly increased levels of lactate in the 
extracellular spent growth medium suggested a higher glycolytic flux present in both 
populations. Interestingly, lactate concentration levels in the intracellular environment were 
significantly higher only in the case of the residual population. Additionally, the reduced 
pyruvate levels compared to the concentration by which pyruvate was detected in pure growth 
media (i.e. growth medium prior to its addition to the cell cultures), were also suggestive of an 
increased pyruvate consumption in both states. Overall, the aforementioned results pointed 
towards an enhanced glycolytic phenotype which was present in tumor and residual cells.  
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Figure 18: The metabolic profile of residual cells is more similar to the tumor than the control state. Heatmap 
of all intracellular metabolites quantified with the targeted metabolomics method (GC-MS) for the control (never 
induced and wild type), tumor and residual populations (hierarchical bi-clustering, pearson correlation).  
Glutamine is an important amino acid involved in several metabolic pathways, 
including TCA cycle anaplerosis, nucleotide metabolism, glutathione generation and redox 
homeostasis49. Glutamine concentration pools were significantly decreased in tumor cells, 
both intracellularly and extracellularly, indicating thus an increase in glutamine catabolism 
(Figure 19-21). Residual cells displayed a decrease in extracellular glutamine too, with the 
concentration pools exhibiting a tendency towards restoration by approximating the levels 
found in normal cells. Glutamine can generate glutamate whose intracellular abundance was 
only slightly increased and to a similar extent in both tumor and residual cells. Subsequently, 
glutamate is coupled to multiple pathways49, including entering the TCA cycle after conversion 
to alpha-ketoglutarate. In addition, glutamate is involved in the biosynthesis of proline, which 
was significantly increased in both populations, intracellularly and extracellularly. Collectively, 
these results highlighted common alterations in glutamine and proline metabolism in tumor 
and residual cells, albeit with varying degrees of magnitude in the residual population for the 
different sub-pathways. 
Since glucose and glutamine are major carbon sources contributing to TCA cycle, and 
a deregulation in their pathways was observed for tumor and residual cells, we next examined 
the concentration levels of TCA cycle intermediates. Alpha-ketoglutarate and 2-
hydroxyglutarate were significantly decreased in the tumor samples, while no significant 
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changes were detected for the residual cells. However, the residual population exhibited a 
significant increase for the metabolites further downstream of alpha-ketoglutarate, namely 
succinate and fumarate (Figure 19-21).  
 
Figure 19: Metabolic alterations in the residual and tumor population. Boxplots showing selected cases of 
significantly altered metabolites (limma analysis, Benjamini-Hochberg adjusted p value ≤ 0.01, see methods) in the 
spent growth medium of control (never induced and wild type), tumor and residual cells. The concentrations of the 
respective metabolites in the growth media prior addition to the cell cultures (denoted as media) are also depicted. 
Marked with an asterisk are selected significant metabolites from the intracellular samples. The concentrations are 
measured as signal intensities (area under the curve) and are depicted in the log2 scale.  
Malate was also increased, albeit the change was statistically less powerful. Tumor 
cells displayed increase only for succinate, with the relative change being lower than the 
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observed one in the residual population (Figure 21 and 22). However, both succinate and 
fumarate were detected in the spent growth medium of tumor cells with significantly increased 
levels (Figure 20). Succinate can be released from the cells, although the process is poorly 
understood so far134. Concomitantly, succinate’s intracellular accumulation can derive from 
multiple pathways, which apart from an altered TCA cycle activity, include the catabolism of 
the branched chain amino acids isoleucine and valine, the glutamine-derived and TCA cycle 
by-passing GABA shunt pathway, or from fumarate produced from aspartate catabolism, urea 
cycle and purine nucleotide cycle through a reversal of the succinate dehydrogenase activity 
(SDH)135. Overall, we detected changes in TCA cycle with differential behaviors for specific 
metabolic intermediates between the two populations. Interestingly, we observed a 
preferential accumulation of succinate and fumarate in the intracellular space of residual cells, 
while for the case of tumor cells both metabolites were released in the extracellular 
environment. 
Apart from the aforementioned alterations, we additionally identified changes in 
metabolites and metabolic pathways connected to TCA cycle, namely aspartate and urea 
cycle (Figures 20 and 21). Mammalian cells can uptake aspartate from the extracellular 
environment, however the process is often inefficient136. As a result, aspartate is generated 
from oxaloacetate which is connected either to TCA cycle62,63, or in specific contexts to 
glycolysis80. Aspartate was significantly decreased in both residual and tumor populations, 
intracellularly and extracellularly. This decrease, compared to aspartate’s levels in the pure 
media samples and in the spent growth medium of normal cells, was suggestive of an 
increased catabolism. Aspartate is coupled to nucleotides, as it is an essential nitrogen and 
carbon source for their biosynthesis100. For both populations, we observed a significant 
increase in the intracellular concentration pools of metabolites linked to nucleotides, namely 
uracil and beta-alanine (Figure 20). In addition, aspartate is also linked to urea cycle, where 
argininosuccinate synthase (ASS1) utilizes aspartate and citrulline to synthesize 
argininosuccinate137. We found urea and ornithine to be the second most increased 
metabolites after lactate in the extracellular medium of both tumor and regressed cells, 
indicative of an enhanced urea cycle (Figure 19). From the intracellular samples, ornithine was 
significantly increased in the tumor population, and a minor, albeit significant, increase in the 
regressed cells was also observed. Ornithine in turn is involved in the generation of 
polyamines138 and the biosynthesis of proline139, which, as described above, was also 
significantly increased in tumor and residual population (Figures 19-21). Finally, urea cycle 
generates fumarate139 that can further fuel the TCA cycle. Overall, the aforementioned results 
described significant alterations along the urea pathway interconnected to alterations in 
aspartate, TCA cycle and proline metabolism (Figure 19-21).  
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To conclude, additional affected pathways involved free fatty acids (i.e. cholesterol, 
stearate, palmitate) which were significantly decreased in the case of tumor cells (Figure 23). 
For the residual population, the concentration pools of the aforementioned fatty acids 
approximated the levels detected in normal cells. An exception was the myristic acid, which, 
although unaltered in tumor cells, exhibited a two-fold increase in the case of residual cells. 
Glycerol-3-phosphate was another metabolite specifically increased only in residual cells. 
Alterations in the concentration pool of this metabolite could be connected to glycerolipid 
metabolism, as well as to glycerol-3-phosphate shuttle utilized for electron transport between 
the cytoplasm and the mitochondria, coupling thus glycolysis and oxidative phosphorylation. 
Finally, other significant changes observed in both states included increased histidine, taurine 
and N-acetyl-aspartate levels, as well as in amino acids, with the respective changes following 
varying degrees of magnitude between the two populations (Figures 20 and 21).  
To understand whether the above metabolic alterations were reflected in the 
expression of the respective genes, the transcript levels, as defined by the RNA-sequencing 
analysis, were examined. Utilizing the same transcriptional data, reporter metabolite analysis 
was performed to predict which metabolites were likely to change as a further verification to 
the metabolomics data, as well as to capture potential changes in metabolites that were not 
included in the targeted method (Katharina Zirngibl and Ksenija Radić Shechter, PhD theses). 
Moreover, flux predictions based on a genome-scale reconstructed mouse model were also 
estimated (Katharina Zirngibl and Ksenija Radić Shechter, PhD theses). An overview of all the 
acquired levels of information and predictions is presented in Figures 21 and 22 for the tumor 
and residual population, respectively. Focusing on the residual state, the transcript levels of 
glucose transporters as well as the majority of the glycolytic enzymes were increased 
compared to the normal state. In addition, specific enzymes in the urea cycle were also 
elevated, as well as the mitochondrial transporter SLC25A13 that facilitates the exchange of 
aspartate and glutamate connected to the urea cycle. Subsequently, the predictions 
suggested alterations in several glycolytic intermediates, the urea and nitric oxide metabolites, 
pyrimidine nucleotides and in the pentose phosphate pathway. Finally, flux changes were 
predicted for glycolysis (increase) and two reactions in the TCA cycle (decrease). For the 
tumor state, similar to the residual cells alterations were observed and predicted. Collectively, 
the transcriptional changes and predictions were in agreement with the metabolic phenotype 
of the residual and tumor populations. 
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Figure 20: Global overview of central carbon metabolic alterations of the residual population compared to 
the control state. The figure encompasses all available information acquired from targeted metabolomics 
measurements, transcriptional changes of the metabolic enzymes, reporter metabolite analysis based on the 
transcriptional data, and flux predictions based on a genome-scale reconstructed mouse model (Ksenija Radić 
Shechter, PhD thesis). 
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Figure 21: Global overview of central carbon metabolic alterations of the tumorous population compared to 
the control state. The figure encompasses all available information acquired from targeted metabolomics 
measurements, transcriptional changes of the metabolic enzymes, reporter metabolite analysis based on the 
transcriptional data, and flux predictions based on a genome-scale reconstructed mouse model (Ksenija Radić 
Shechter, PhD thesis). 
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Taken together, the targeted metabolomics data highlighted that the residual cells, 
despite the phenotypic similarity to their normal counterparts, preserved specific metabolic 
alterations reminiscent of the tumorous population. This metabolic memory was also reflected 
at the transcriptional level of the corresponding enzymes for the majority of the reactions. The 
metabolic particularities that characterized the residual population pointed towards an 
enhanced glycolysis and urea cycle, alterations in proline metabolism and accumulation of 
specific TCA cycle intermediates.  
Ex vivo and in vivo validations support the altered glycolysis and urea 
cycle metabolic signatures in the residual population 
We next aimed to validate in the mouse model system the key metabolic alterations 
observed in the in vitro three dimensional cell cultures. For this purpose, animals 
corresponding to the regressed state (i.e. mice treated with doxycycline for four to six weeks 
to induce tumor formation followed by doxycycline withdrawal for nine weeks for tumor 
regression), as well as age-matched wild type animals (i.e. wild type mice treated with 
doxycycline followed by doxycycline withdrawal for the same period) were utilized to isolate 
the mammary glands. The isolated tissues were cultivated in the presence of uniformly labeled 
glucose, [U-13C]-glucose, for 8 hours, and intracellular and extracellular samples were 
collected to measure 13C-lactate levels. In parallel, the same experiment was performed with 
unlabeled glucose for extracellular targeted metabolomics analysis.  
From the ex vivo labeling experiment, we detected statistically higher intracellular 13C-
lactate pools in the regressed mammary glands compared to the control ones (Figure 22d). In 
the ex vivo extracellular metabolomics experiment, the regressed mammary glands when 
compared to the control ones, showed a trend for decrease in glucose levels and an increase 
in lactate levels, albeit not statistically significant (Figure 22b). Overall, the labeling and 
extracellular metabolomics results combined suggested that the relative glucose contribution 
to lactate was higher in the regressed cells compared to the control state.  
The extracellular metabolic profile of the regressed mammary glands highlighted once 
again their distinctive metabolic nature from the control state (Figure 22a), and verified the 
previously defined alterations in the urea cycle as indicated by the higher extracellular 
abundances in urea, ornithine and putrescine (Figure 22b). Pyruvate extracellular levels 
exhibited the same alteration as in the three dimensional cell cultures, being significantly lower 
in the regressed state compared to the control (Figure 22b). Aspartate extracellular pools 
displayed an opposite alteration than the one observed in the cell cultures, being significantly 
higher in the regressed state compared to the control. Hypotheses regarding this 
disagreement could be attributed to the fact that aspartate uptake from the cells is usually not 
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an efficient process which combined with the differential nutrient accessibilities in a ex vivo 
cultivated tissue sample compared to the cell culture system results in a decreased uptake 
and hence higher extracellular levels. It should also be noted that the ex vivo experiments 
were performed after a cultivation period of 8 hours, compared to the in vitro cell cultures 
where the extracellular samples were corresponding to the spent medium of the last 24h of 
cultivation. The latter could also explain why the extracellular unlabeled glucose and lactate 
concentration changes, albeit exhibiting the expected trend, did not reach a statistical 
significance. 
 
Figure 22: Ex vivo and in vivo validation supports the altered glycolysis and urea cycle metabolic signatures 
in the residual population. (a) Principle component analysis of extracellular metabolic profiles of regressed and 
control mammary glands. Color legend same as in panel (d). (b) Boxplots of selected extracellular metabolites of the 
regressed and control mammary glands. Apart from glucose, lactate and succinate, all other metabolites are 
statistically significant (limma analysis, Benjamini-Hochberg adjusted p value ≤ 0.01). The concentrations are 
measured as signal intensities (area under the curve), and are depicted on the log2 scale. Color legend same as in 
panel (d). (c) Arginase1 verification on the tissues of animals 9 weeks off doxycycline (regressed mammary glands) 
compared to healthy age-matched controls. Left panel: IF stains – E-cadherin in red, ARG1 in green; nuclei stained 
with DAPI (blue). Scale bar: 50 µm. Right panels: Percentage (upper) and mean intensity (lower) of ARG1 positive 
cells (Ksenija Radić Shechter, PhD thesis). Color legend same as in panel (d). (d) In vivo intracellular metabolic 
verifications on the regressed and control mammary glands. Upper panel: Intracellular lactate labeling from [U-13C]-
glucose (M3 indicates the mass isotopomer labeled in three carbons). Lower panel: enzymatic activity for nitric oxide 
synthase (NOS). 
 
To further monitor the urea cycle, regressed and control mammary glands isolated 
from the same animals utilized for the aforementioned metabolomics experiments, were 
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assessed for the enzymatic activity of the nitric oxide synthase (NOS) which catalyzes the 
production of nitric oxide from arginine. The particular enzyme was chosen owing to the high 
transcriptional levels of NOS2 in the regressed cells compared to the control and tumor state. 
The lysates of the regressed mammary glands displayed a significantly higher activity than 
the control ones (Figure 22d). In addition, immunofluorescence staining for another enzyme 
of the urea cycle, that of arginase 1 (ARG1) which catalyzes the conversion of arginine to 
ornithine and urea, was significantly increased in the regressed mammary glands compared 
to the control (Figure 22c). The quantification of the number of ARG1+ cells, as well as the 
comparison of the mean intensity in ARG1+ cells on the analyzed tissue sections were also 
increased in the regressed state compared to the control (Figure 22c) (Ksenija Radić Shechter 
Shechter, PhD thesis). 
Collectively, the ex vivo [U-13C]-labeling, extracellular metabolomics, NOS enzymatic 
assay and immunofluorescence imaging verified the metabolic changes observed in the three 
dimensional cell cultures for two key metabolic characteristics present in the residual 
population, namely an enhanced glycolysis and urea cycle activity.  
Discussion and Outlook 
Cancer metabolic alterations are nowadays a well-established phenomenon. Yet, far 
less is known for the metabolic physiology underlying residual cells that survive therapy and 
can contribute to cancer recurrence. This limitation is largely attributed to the difficulties in 
characterizing and obtaining these populations in vivo. In the presented study, to explore the 
metabolic particularities of residual cells, we employed three dimensional primary epithelial 
cell cultures derived from a mouse model of breast cancer based on the doxycycline-inducible 
overexpression of the oncoproteins MYC and HER2. The addition of doxycycline followed by 
withdrawal could thus simulate cancer induction, formation and regression. We demonstrated 
that regressed cells, although phenotypically similar to their normal counterparts and despite 
the absence of oncogenic signaling, they still maintained a metabolic phenotype largely 
mnemonic of the tumorous population. The residual cells were mainly characterized by an 
enhanced glycolysis, deregulated TCA cycle and urea cycle activity. While the transcriptional 
profile of the residual cells was closer to the normal than the tumorous state, the transcriptional 
changes of the metabolic enzymes specific to the altered metabolic pathways were largely in 
agreement with the metabolic phenotype. The metabolic phenotype was further supported by 
reporter metabolite analysis based on the transcriptional data, and flux predictions based on 
a genome-scale reconstructed mouse model (Ksenija Radić Shechter and Katharina Zirngibl, 
PhD theses). Two of the main metabolic alterations, namely the deregulated glycolysis and 
urea cycle, present in the three dimensional cell cultures, were further verified in the in vivo 
mouse model. Finally, evidence of both metabolic phenotypes were detected in breast cancer 
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disease patients after treatment (which approximate the in vitro regressed state), 
substantiating the potential relevance in a human setting (Ksenija Radić Shechter and 
Katharina Zirngibl, PhD theses). 
Both MYC and HER2 oncoproteins have been connected to enhanced glycolysis 
through the upregulation of glucose transporters and several enzymes along the glycolytic 
axis, including hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA)140. Apart from 
glycolysis, MYC oncoprotein is known to enhance glutamine catabolism by upregulating both 
glutamine transporters and glutaminase (GLS), the enzyme which converts glutamine to 
glutamate74,141, and to promote proline accumulation by upregulating the enzymes involved in 
its biosynthesis and inhibiting the enzymes catalyzing its degradation142. Moreover, MYC is 
also implicated to urea deregulation by enhancing the expression of two enzymes of the cycle, 
namely argininosuccinate synthase 1 (ASS1) and ornithine decarboxylase (ODC)137. 
Concomitantly, deregulation of the aforementioned pathways has been connected to offer 
several advantages, mainly by supporting the biosynthetic requirements of the highly 
proliferative cancer cells. Consistent with the above, the presence of such metabolic 
alterations in the MYC/HER2-induced tumor state was in agreement with expectations. 
However, the persistence of this phenotype in the regressed cells, albeit with variations or 
differential responses along the different pathways, was unexpected considering the absence 
of the oncogenic signals and their non-proliferative nature. On the other hand, this persistence 
is suggestive that the metabolic alterations are not merely a consequence of the oncogenic 
inputs, but continue to operate and possibly mediate additional modulatory functions 
sustaining a potential in the dormant population. Along these lines, it has been shown that a 
high glucose flux does not always correlate with the proliferative status of the cells143, and a 
growing body of evidence support the additional roles that glycolysis could serve. For instance, 
the biosynthesis of certain metabolites with epigenetic-related functions are dependent on 
glycolysis. Acetyl-CoA or ADP-ribose, whose carbons mainly derive from glucose, are used 
for acetylation and poly-(ADP-ribosyl)ation of histones, respectively. These histone 
modifications are not only connected to gene expression regulation7, but their presence is 
essential for DNA damage repair mechanisms too29. It is thus interesting to speculate whether 
a high glycolytic flux in the residual population could be linked to sustainability of the genomic 
integrity.  
Certain glycolytic related metabolites can additionally act as signaling molecules. 
Accumulation of lactate in the intracellular environment leads to its binding in specific proteins 
and their stabilization, a process which in turn results in downstream signaling cascades 
promoting cell survival and growth144. Intracellular lactate catabolism has also been connected 
to breast cancer stemness through the generation of acetyl-CoA and subsequent epigenetic 
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modifications145. Interestingly, in our data, lactate intracellular pools were significantly higher 
only in the residual population compared to the tumor cells where lactate was only altered in 
the extracellular spent growth medium. Similarly to lactate, two metabolites of TCA cycle, 
namely succinate and fumarate, were significantly accumulated specifically in the intracellular 
space of residual cells, with the tumor population exhibiting higher levels only in the 
extracellular environment. Notably, both succinate and fumarate are implicated in epigenetic 
modifications through direct inhibition of the alpha-ketoglutarate dependent demethylases that 
confer histone and DNA demethylation18. Additionally, succinate, like lactate, can operate as 
a signaling molecule, binding and stabilizing proteins, including the hypoxia inducible factor 1 
(HIF1α). This protein-metabolite interaction further promotes the glycolytic phenotype through 
HIF1α-mediated events146. Along the same direction, nitric oxide, produced by nitric oxide 
synthase in the urea cycle whose activity was significantly increased in the residual population, 
represents another metabolic intermediate with multiple roles including signaling functions that 
further promote oncogenic pathways147.  
Overall, the aforementioned paradigms highlight how metabolic alterations are not 
merely required to support the oncogene-induced anabolic requirements, but also actively 
participating in cancer robustness, fate and recurrence through epigenetic and signaling 
events amongst other functions. Why and how this tumorous-like metabolic phenotype is 
maintained in the regressed state is an important question to address. Preliminary results from 
our research group (Katharina Zirngibl and Ksenija Radić Shechter) show that the DNA 
methylation landscape is largely similar between tumor and regressed cells and distinct from 
the normal state. It would be thus interesting to explore whether progressive alterations in the 
epigenetic landscape proceed or parallels metabolic alterations. In addition, the identified 
metabolic changes offer promising avenues of (combinatorial) cancer treatment at the 
metabolic level - together with a disease progression mapping showing points of intervention 
could potentiate the therapeutic efficacy. Finally, our metabolic results highlight another 
perspective in cancer monitoring schemes after treatment, setting the question whether the 
metabolic physiology, rather than phenotypic markers, could be utilized to assess the results 
of cancer elimination treatments and monitor cancer recurrence.   
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Chapter III: Metabolic response of cancer cells to inhibition of 
lactate dehydrogenase and monocarboxylate transport 
activities 
As mentioned in the previous chapters, cancer cells aberrant metabolic nature is a 
major transformative effector of their complex pathophysiology. As a consequence of this, 
efforts are made over the past years to target important facilitators of deregulated metabolic 
pathways. Enhanced glycolysis, which is characterized by a high glucose consumption 
towards lactate production, is the most commonly recurring alteration across many cancer 
types41. Considering the pleiotropic roles of lactate, including as a carbon source and 
signalling molecule enhancing proliferation and metastatic potential, of the most attractive 
metabolic targets are the enzyme lactate dehydrogenase A (LDH) and the monocarboxylate 
transporters (MCTs) involved in lactate production and transport, respectively. However, the 
development of potent inhibitors has proven a challenging task - none of the developed LDH 
inhibitors has progressed into clinical trials so far, either for reasons of being in vivo inactive 
or due to unfavourable pharmacokinetic properties57,148,149. MCT1 offers a promising target 
and is currently in phase I clinical trials in UK with potential progression to phase II150 
(www.clinicaltrials.gov). Towards a mechanistic understanding of the perturbations of lactate 
node, the current study, carried out in collaboration with Merck Serono GmbH, aimed at 
investigating the network-wide metabolic response upon inhibition of LDHA and MCT1 and 2 
in cancer cell lines. Metabolic profiling with Gas Chromatography – Mass Spectrometry was 
utilized to identify the metabolite concentration changes, while [U-13C]-glucose and [U-13C]-
glutamine labelling were employed to assess flux changes in the central carbon metabolism.  
Treatment with LDHA and MCT1 and 2 inhibitors results in distinctive 
metabolic profiles characterized by opposite alterations in glycolysis 
and TCA cycle 
To track the metabolic effects derived from the inhibition of LDHA and MCT1 and 2 
(hereafter denoted as MCT1/2), SNU398 cells were treated for 1 and 4 hours with either of 
the inhibitors, and intracellular and extracellular samples were collected for metabolomics 
analysis via Gas Chromatography - Mass Spectrometry. Control samples included untreated 
cells and cells treated with DMSO. In total, we were able to reliably quantify 57 and 30 known 
metabolites in the intracellular and extracellular samples, respectively. The treatments 
affected the metabolic physiology of the cells, resulted in distinctive intracellular metabolic 
profiles between the two treated and the control states (Figure 23b). As expected, treatment 
with the LDHA inhibitor, which targets the lactate production from pyruvate, induced 
significantly decreased lactate concentration pools in the intracellular environment, already at 
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1h post-inhibition (Figure 23d). Alterations in the extracellular medium were observed only at 
4h post-treatment (Figure 23c). Even though intracellular lactate was decreased, endogenous 
pyruvate remained largely unchanged. However, in the extracellular environment pyruvate 
was significantly increased, being in fact the most significantly altered extracellular metabolite 
(Figure 23c). Apart from the aforementioned changes, cells treated with the LDHA inhibitor 
exhibited significant alterations for 18 intracellular metabolites, mapped mainly to increased 
upper glycolytic metabolites (i.e. fructose 1.6-bisphosphate), and decreased intermediates of 
lower glycolysis (i.e. phosphoenolpyruvate) and TCA cycle, expect citrate, whose levels 
although significantly changed at 1h, approximated the levels of the control cells after 4 hours 
of inhibition (Figure 23d). Additional intracellular changes included an overall increase in 
unknown sugar phospho-compounds. Interestingly, we also observed significant increases in 
intracellular fructose and sorbitol levels (Figure 23d). 
The MCT1 and 2 are involved in the bidirectional transportation of lactate, as well as 
pyruvate and ketone bodies, mainly inside and outside of the cells, with the direction of the 
transportation being dependent on the concentration gradients. Consistent with expectations, 
inhibition of the MCT1/2 resulted in an almost five-fold accumulation of the intracellular lactate 
from the first hour of treatment (Figure 23e). No greater accumulation was observed in the last 
time point. In the extracellular environment, lactate levels started to reduce only at four hours 
post-inhibition (Figure 23c). In addition to lactate, we observed that pyruvate extracellular 
levels were largely depleted in the extracellular medium, suggesting a strong inhibition in the 
export of pyruvate too (Figure 23c). Despite this, intracellular pyruvate levels remained 
relatively unchanged. Interestingly, regarding the downstream intracellular metabolic effects, 
the MCT1/2 inhibitor induced an almost reversed metabolic phenotype compared to the one 
induced after treatment with the LDHA inhibitor. More specifically, there was a significant 
decrease of the upper glycolytic metabolites, and an accumulation of TCA cycle intermediates 
(Figure 23e and 24). Finally, similar alterations between the two treatments were detected for 
the following metabolites: N-acetylserine, N-acetylglutamate, gluconate and taurine. These 
metabolites displayed decreased intracellular levels in the cells treated with either of the two 
inhibitors compared to the control state (Figure 24d and 24e). In the extracellular space, 
glutamine levels were significantly decreased at 4h post-treatment with either of the inhibitors 
(Figure 23c).  
Overall, the initial metabolic profiling matched the expectations regarding the 
metabolites directly affected from the inhibitors treatment (i.e. lactate and pyruvate). The 
opposite concentration pools of upper glycolysis and TCA cycle intermediates (Figure 24) 
pointed to interesting flux re-organizations following the inhibitors treatment. Along these lines, 
as a next step, we were interested to compare the relative pathway activities and the relative 
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contributions of the two major carbon sources, glucose and glutamine, that feed glycolysis and 
TCA cycle, upon treatment with the two inhibitors.  
 
Figure 23: Metabolic alterations after inhibition of lactate dehydrogenase and monocarboxylate transporters 
1 and 2. (a) Abstract schematic representation of the main metabolic targets and the respective metabolic pathways. 
(b) Principle component analysis based on the intracellular metabolic profiles of control cells (treated with DMSO and 
untreated), cells treated with the LDHA inhibitor (LDHi) and cells treated with the MCT1/2 inhibitor (MCTi), for 1h and 
4h. Untreated cells prior treatment (0h) were also analyzed. (c) Extracellular metabolite abundances (after 4h of 
treatment) (abundances are measured as area under the curve, AUC). Color scheme is the same as in panel b. Error 
bars denote standard error of the mean (sem) for 3 biological replicates. (c) and (d) Barplots for the statistically 
significant intracellular metabolites depicting the fold change in treated cells relative to control DMSO samples (based 
on limma analysis, see methods).  
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Figure 24:  Overview of metabolic effects on glycolysis and TCA cycle upon inhibition of lactate 
dehydrogenase and monocarboxylate transporters 1 and 2. An abstract network of glycolysis and TCA cycle is 
depicted along with the significant changes in the concentration pools of cells treated with the lactate dehydrogenase 
inhibitor (LDHi) or with the monocarboxylate transporters 1 and 2 inhibitor (MCTi) compared to the control cells 
(treated with DMSO). Red and green corresponds to increased and decreased concentrations in the inhibitors treated 
samples compared to the control cells.  
Inhibition of MCT1 and 2 ablates pyruvate export but not lactate 
To examine glucose metabolism, SNU398 cells were treated for 1, 2, 4, 6 and 8 hours 
with either of the inhibitors in growth medium supplemented with [U-13C]-glucose, and both 
intracellular and extracellular samples were collected to monitor 13C carbon incorporation in 
glycolytic and TCA cycle intermediates. Following treatment with the MCT1/2 inhibitor, we did 
not detect any labelled pyruvate in the extracellular environment, indicating a stable inhibition 
of its export (Figure 25). On the other hand, extracellular lactate labeled in all three carbons 
(M3 isotopomer) started to increase after 4h of treatment (Figure 25) which was suggestive of 
the induction of compensatory mechanisms contributing to its export. Recently published data 
showed that MCT1 inhibition in breast cancer cell lines does not eventually affect lactate 
export owing to induced upregulation of the monocarboxylate transporter MCT4 which 
facilitates compensatory lactate export151. When cells were treated with the LDHA inhibitor, 
both intracellular and extracellular M3 lactate isotopomer levels started to increase after 4h of 
inhibition pointing to a possible loss of inhibitor’s activity (Figure 25). Overall, these results 
indicated that the MCT1/2 inhibitor strongly affects pyruvate export and has mediocre effects 
on lactate export, which instead starts to increase after 4h of treatment through compensatory 
export mechanisms mediated by other MCT transporters, including MCT4. LDHA inhibitor 
showed an activity loss after 4h.  
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Figure 25: Labeling kinetics of pyruvate and lactate upon treatment with the lactate dehydrogenase inhibitor 
or the monocarboxylate transporters 1 and 2 inhibitor.  Labeling of pyruvate (upper panels) and lactate (lower 
panels) from [U-13C]-glucose in intracellular (a) and extracellular (b) samples after treatment with the LDHA inhibitor 
(LDHi) or the MCT1/2 inhibitor (MCTi), compared to control cells (DMSO-treated). The measurements were acquired 
over time, for five points corresponding to 1h, 2h, 4h, 6h and 8h after treatment with the inhibitors or DMSO and [U-
13C]-glucose addition. M0 to Mn indicates the different mass isotopomers (M0 denotes that zero carbons are labeled, 
and Mn denotes that n number of carbons are labeled). Error bars denote standard error of the mean (sem) for three 
biological replicates. 
 
Inhibition of MCT1/2 or LDHA induces a decreased lipid biosynthesis flux 
As a next step, we aimed to monitor whether there were alterations in glucose 
contribution to TCA cycle metabolites following inhibitors treatment. To estimate glucose 
carbon entry to TCA cycle, we calculated the ratio of total labeled carbon contribution in citrate 
(FC citrate) to total labeled carbon contribution in pyruvate (FC pyruvate) (Figure 26). Of note, 
we estimated the ratio to labeled pyruvate in order to exclude upstream changes in glycolysis. 
We found that the ratio was similar in both inhibitors and no different from the control cells 
(Figure 26). However, for the case of MCT1/2 inhibitor, the isotopomers of TCA cycle 
intermediates generated from multiple rounds of the cycle were increased (calculated as the 
ratio of M4 citrate to M2 citrate) (Figure 26). Same trend was observed for LDHA inhibition, 
however to a lesser extent (Figure 26). This increase indicated that less carbon leaves the 
TCA cycle for lipid biosynthesis at the level of citrate, and hence less anaplerosis of the TCA 
cycle takes place. The reduced biosynthetic flux was further confirmed by the ratio of N-acetyl-
aspartate M2 isotopomer to pyruvate M3 isotopomer (again to exclude any upstream changes 
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in glycolysis), which can be used as an estimate for the acetyl-moiety derived from acetyl-CoA 
(Figure 26).  
 
Figure 26: Effects on glucose’s contribution to the central carbon metabolic pathways glycolysis and TCA 
cycle upon treatment with the lactate dehydrogenase inhibitor or the monocarboxylate transporters 1 and 2 
inhibitor. The effects are depicted together with a schematic representation of glycolysis and TCA cycle pathways, 
and the respective carbon atom (circles) transitions for specific metabolites derived using [U-13C]-glucose as a tracer. 
Filled black and grey circles denote 13C carbons derived from the first and second round of oxidative TCA cycle, 
respectively. 12C carbons are depicted as empty circles. M0 to Mn indicates the different mass isotopomers (M0 
denotes that zero carbons are labeled, and Mn denotes that n number of carbons are labeled). Note that not all 
possible isotopomers are depicted. For glycerol 3-phosphate only the ion that corresponds to the two carbon fragment 
was detected and quantified. Error bars denote standard error of the mean (sem) for three biological replicates. 
Abbreviations: N-ac-asp, N-acetyl-aspartate; AcCoA, Acetyl-Coenzyme A; cit, citrate; akg, alpha-ketoglutarate; suc, 
succinate; fum, fumarate; mal, malate; asp, aspartate; citM4, citrate M4 isotopomer; citM2, citrate M2 isotopomer; N-
ac-aspM2, N-acetyl-aspartate M2 isotopomer; pyrM3, pyruvate M3 isotopomer, FCcit, total carbon contribution in 
citrate; FCpyr, total carbon contribution in pyruvate (see texts for details). 
Both inhibitors, albeit more strongly the one targeting LDHA, had an increase in the 
glycerol 3-phosphate M2 isotopomer, possibly reflecting a compensatory route for 
NAD+/NADH regeneration which is disturbed by the inhibition of pyruvate to lactate (Figure 
26). As a final step, we estimated the glucose uptake rates, and we found an increase only for 
the LDHA inhibitor (appendix, Figure 32). Taken together, these data revealed that although 
there was no alteration in glucose uptake rates and glucose’s entry in TCA cycle, both 
inhibitors induced a decrease in the biosynthetic flux, stronger for the case of MCT1/2 inhibitor, 
which is suggestive of a reduction in the proliferative status of the cells. 
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Contribution of glutamine to TCA cycle is altered after treatment with 
LDHA or MCT1/2 inhibitors 
Glutamine is a major carbon source for TCA cycle anaplerosis, and as a next step we 
aimed to study whether the inhibitors induce changes in glutamine contribution to TCA cycle 
metabolites. For this purpose, the same experimental scheme as before was performed using 
uniformly labelled glutamine, [U-13C]-glutamine. Following treatment with the inhibitors, we 
identified a significant decrease in the contribution of glutamine to the TCA cycle for both 
cases, but even more pronounced in the inhibition of LDHA (Figure 27). Glutamine enters TCA 
cycle at the level of alpha-ketoglutarate which subsequently is converted to succinyl-CoA and 
then to succinate. Interestingly, in the control cells and in cells treated with the LDHA inhibitor, 
we observed a substantially diluted labelling in succinate (Figure 27). We calculated that only 
40% originated from alpha-ketoglutarate, with the rest deriving from an unlabeled source. 
However, in the case of MCT1/2 inhibition most of the succinate originated from alpha-
ketoglutarate (Figure 29).  
Anaplerosis of the TCA cycle flux can take place in different intermediates which 
results in label dilution if the source molecules are not labelled. Possible sources that could 
contribute to succinate dilution are odd fatty acids and branched chain amino acid catabolism 
(i.e. valine, isoleucine, leucine) that feed the TCA cycle at the level of succinyl-CoA. Branched 
chain amino acids catabolism starts in the cytoplasm and continues in the mitochondria. 
Amongst the produced metabolites are small organic compounds (i.e. 2-hydroxybutyric acid, 
acetoacetate), and studies have shown that their transportation, at least inside and outside of 
the cell, can be facilitated by MCTs. Our succinate labeling dilution results rather indicated 
that MCTs can also contribute to an intracellular trafficking between the different 
compartments, and more specifically between the cytoplasm and mitochondria. This is in 
agreement with a recent study where immunofluorescence indicated an intracellular 
localization signal for MCT1152. As such, succinate increased labeled isotopomers after 
treatment with the MCT1/2 inhibitor could be attributed to an inhibitory effect within the cell, 
targeting the transportation of small organic acids between the different compartments. 
Analysis of the isotopomers for the rest of the TCA cycle intermediates indicated that, despite 
the substantial dilution of succinate in the control cells and cells treated with the LDHA 
inhibitor, there was no dilution in the labeling of malate (Figure 27). In addition, the labelled 
fraction of malate was higher than that of succinate (~90%), which indicated the existence of 
two separate pools of succinate that are not in complete exchange. Moreover, we calculated 
the fraction of malate originating from alpha-ketoglutarate to quantify the label dilution in 
malate and we found it similar in all cases (Figure 27). There was a marginal increase and 
decrease in the reductive glutamine metabolism after MCT1/2 and LDHA inhibition, 
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respectively, albeit not significant. Finally, glutamine uptake rates were decreased only for the 
case of LDHA inhibitor (appendix, Figure 32). Taken together, these results indicated less 
glutamine contribution in the TCA cycle after inhibition of LDHA. Additionally, we identified an 
interesting point where MCT1/2 inhibitory effects could be facilitated by targeting intra-
organelle transportation of small organic acids but further validation of this mechanism is 
required. 
 
Figure 27: Effects on glutamine’s contribution to TCA cycle after treatment with the lactate dehydrogenase 
inhibitor or the monocarboxylate transporters 1 and 2 inhibitor. The effects are depicted together with a 
schematic representation of the TCA cycle pathways, and the respective carbon atom (circles) transitions for specific 
metabolites derived using [U-13C]-glutamine as a tracer. Filled dark grey and grey circles denote 13C carbons derived 
from the first and second round of oxidative TCA cycle, respectively. 12C carbons are depicted as empty circles. M0 
to Mn indicates the different mass isotopomers (M0 denotes that zero carbons are labeled, and Mn denotes that n 
number of carbons are labeled). Note that not all possible isotopomers are depicted. Error bars denote standard error 
of the mean (sem) for three biological replicates. Abbreviations: cit, citrate; akg, alpha-ketoglutarate; fum, fumarate; 
mal, malate; citM5, citrate M5 isotopomer; citM3, citrate M3 isotopomer; akgM5, alpha-ketoglutarate M5 isotopomer; 
akgM3, alpha-ketoglutarate M3 isotopomer; glnM5, glutamine M5 isotopomer; sucM4, succinate M4 isotopomer; 
sucM2, succinate M2 isotopomer; malM4, malate M4 isotopomer. 
 
LDHA inhibition points to alterations in fructose metabolism  
Owing to the intracellular opposite metabolic phenotype following LDHA and MCT1/2 
inhibition, we decided to treat cells with both inhibitors simultaneously and measure the 
intracellular and extracellular metabolic profiles. Of note, calculation of the proliferation rates 
after the treatment did not result in significant changes compared to the control cells (Merck 
data). In the combinatorial treatment, the MCT1/2 inhibitor appeared as the dominant 
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metabolic effector (Figure 28a), and most of the induced changes in the metabolic 
concentration pools resembled the ones found after treatment with the MCT1/2 inhibitor alone 
(Figure 28a and 28b). Despite this, we observed an interesting pattern in fructose 1.6-
bisphosphate levels, which, although decreased after 1h of treatment, they displayed an 
opposite change at 4h (Figure 28b). In addition, the combinatorial treatment resulted in an 
increase in fructose and sorbitol levels, and several unknown sugar phopho-compounds, 
similarly to the metabolic phenotype observed after treatment with the LDHA inhibitor alone 
(Figure 28c). Overall, the combination treatment pointed to interesting alterations around 
fructose metabolism that seem to be induced from the inhibition of LDHA. This phenotype 
could point to an interesting node connected to the polyol pathway and the conversion of 
glucose to sorbitol and then fructose which can further be degraded (fructolysis) and enter 
glycolysis by skipping the heavily allosterically controlled step of PFK-1153,154. 
 
Figure 28: Metabolic alterations upon dual inhibition of lactate dehydrogenase and monocarboxylate 
transporters 1 and 2 activities. (a) Principle component analysis based on the intracellular metabolic profiles of 
control cells (treated with DMSO and untreated), cells treated with the LDHA inhibitor (LDHi), cells treated with the 
MCT1/2 inhibitor (MCTi), and cells treated with both inhibitors (LDHi&MCTi), for 1h and 4h. Untreated cells prior 
treatment (0h) were also analyzed. Batch A and Batch B denote two distinct biological experiments with three replicate 
per condition each. (b) Barplots for the statistically significant intracellular metabolites depicting the fold change in 
treated cells relative to control DMSO samples (based on limma analysis, see methods). (c) Overlay for the three 
treated conditions of the raw mass ion chromatographs of m/z 217 and 387, which are representative ion fragments 
for sugar phosphate compounds. 
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Summary and Outlook 
Collectively, in the present study we comprehensively mapped at the metabolic level 
the effects exhibited after inhibition of LDHA and MCT1/2, alone and in combination. We 
detected opposite alterations in the concentration pools of metabolites in the glycolysis and 
TCA cycle pathways, reflective of the metabolic rewiring that takes place as a response to 
decreased and increased endogenous lactate levels occurring after the inhibitors treatments. 
Moreover, we identified an interesting deregulation around fructose metabolism induced by 
LDHA inhibition, which could indicate a compensatory mechanism of the cell to continue 
glycolysis by avoiding heavily regulated metabolic nodes. As a consequence of this, inhibitors 
that target the fructolytic pathway (i.e. inhibitors against aldolase b or fructokinase) could be 
evaluated in the future in a combinatorial scheme that could offer better therapeutic potential. 
By employing 13C-labeling, we identified that MCT1/2 inhibitor strongly inhibits pyruvate export, 
but not lactate, which is in agreement with recently published results from other groups151. 
Regarding overall fluxes, for the MCT1/2 inhibitor, even though the glutamine and glucose 
uptake levels were similar to DMSO control cells, the significantly decreased lipid biosynthesis 
in combination with the increased concentrations of TCA compounds could argue to an overall 
lower flux. For the LDHA inhibition, the higher glucose and glutamine uptake rates in 
combination with the lower glutamine contribution to TCA cycle and the decreased TCA 
intracellular concentrations could point to an overall higher flux. Finally, we identified a so-far 
underestimated mechanism of action for the MCT1/2 inhibitor, rendering of further 
characterization, which suggests that its effects could be partially attributed to the attenuation 
of trafficking of small organic molecules within the cell between the different compartments.  
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 Concluding Remarks 
Fundamental nuclear activities, ranging from DNA synthesis to gene regulation, are 
often dependent on small molecules, metabolites, commonly perceived to diffuse from other 
subcellular compartments into the nuclear sites of need. In the present PhD thesis, we 
demonstrate that the HeLa nucleus harbors a functional metabolic network that locally 
produces metabolites with key roles in nuclear processes, including chromatin and RNA 
chemical modifications, and nucleotide metabolism. This nuclear metabolic architecture 
presents hereafter important implications for the regulatory interplay between the metabolic 
state of a cell and gene expression. Considering that the intracellular environment is a rather 
viscous space where the free diffusion of even small molecules could be restricted, or 
metabolites could be siphoned to other metabolic processes until they reach the nucleus, our 
findings suggests how the efficiency of the epigenetic or epitranscriptomic reactions could be 
ensured regarding the accessibility and availability of these required metabolites. The detected 
intra-nuclear produced metabolites are known components of the aforementioned reactions, 
however given metabolites’ increasingly recognized pleiotropic roles, future studies could 
further reveal an additional spectrum of nuclear processes they are associated with, as well 
as potential moonlighting functions of the respective metabolic enzymes. It is enticing to 
hypothesize the existence of additional nuclear metabolic networks apart from the one 
described here, or even smaller distinctive metabolic sub-niches on specific sites within the 
nuclear compartment, and the respective functionalities they could serve. Ultimately, the novel 
concept generated by this research has fundamental extensions relevant for understanding 
genome stability, embryonic development, stem cell differentiation, ageing and tumor 
progression. The complex and dynamic relationship between the latter and metabolism is 
further highlighted by our finding regarding the persistence in regressed cells of a metabolic 
phenotype mnemonic to the tumorous state. This in turn suggests that metabolic alterations 
are not merely a consequence of oncogenes, but could have a pivotal role in maintaining a 
tumorous potential that should further be explored in future studies. Overall these findings 
present broad and far-reaching implications in cancer monitoring schemes and therapeutics 
interventions. 
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Chapter I – Materials and Methods 
Nuclei Purification 
HeLa Kyoto cells were maintained under standard cultivation conditions (37oC, 5% 
CO2) in high-glucose (5g/L) Dulbecco’s modified Eagle medium (DMEM, GlutaMax, Thermo 
Fischer Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Thermo 
Fischer Scientific). For nuclei experiments, the cells were seeded in 245mm plates (2.0 x 106 
cells/plate) and cultivated for 3 days prior to collection. Nuclei collection was adapted from Ori 
and colleagues155. Briefly, cells were washed twice with 10ml PBS (room temperature), 
followed by harvesting with trypsinization. Note that from this step and onwards, all steps and 
buffers were performed in cold conditions. After centrifugation at 500g for 5min at 4oC, the cell 
pellets were washed with 10ml ice cold PBS and centrifuged again using the aforementioned 
conditions. The cell pellet was subsequently resuspended in 7.5ml ice cold hypotonic buffer A 
(50mM Tris-HCl pH7.5, protease inhibitors cocktail, Sigma-Aldri) and incubated on ice for 
30min. Once the cells were swollen, rapture was done utilizing a Dounce homogenizer with 
pestle B. Cell lysis efficiency was monitored via light microscopy. Once cells were efficiently 
lysed, the lysates were centrifuge at 1000g for 8min, at 4oC, the supernatant was removed, 
and the pelleted nuclei were resuspended in 10ml ice cold buffer B (0.25M sucrose, 50mM 
Tris-HCl pH7.5, 25mM KCl, 5mM MgCl2, 2mM DTT, protease inhibitors cocktail) and 
transferred in round-bottom cell culture tubes. Nuclei were centrifuged at 1000g for 8min, at 
4oC, and the supernatant was removed. The nuclei pellets were resuspended in 3ml of buffer 
2C:1B (for recipe of buffer C, see below), and the samples were transferred to an 
ultracentrifuge tube. The sucrose cushion (buffer C, 2.3M sucrose, 50mM Tris-HCl pH7.5, 
25mM KCl, 5mM MgCl2, 2mM DTT, protease inhibitors cocktail) was slowly placed at the 
bottom of the tubes via a wide long needle of at least 18G attached to a luer-lock syringe. The 
samples were centrifuged in a Beckman ultracentrifuge using the SW55Ti rotor at 15000 rpm 
for 30min at 4oC. After centrifugation, the interphase and the supernatant were carefully 
aspirated via vacuum, and the pellet was resuspended in 1ml ice cold buffer B. The nuclei 
were centrifuged at 1000g for 8min, at 4oC, and the step was repeated once more. The 
pelleted nuclei were immediately utilized for 13C-labeling. Alternatively, samples were also 
saved at -80oC for immunoblot analysis.  
13C-labeling experiments in isolated nuclei and cell lysates and 
metabolite extraction 
For the 13C-labeling experiments, the following modified buffer B was prepared: 
0.25M sucrose, 50mM Tris-HCl pH7.5, 25mM KCl, 5mM MgCl2, 2mM DTT, protease inhibitors 
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cocktail, 1mM ATP, 1mM ADP, 1mM FAD, 1mM NAD+. The modified buffer B was 
supplemented with either of the following [U-13C] substrates at a 10mM final concentration: [U-
13C]-pyruvate, [U-13C]-citrate, [U-13C]-glutamine, [U-13C]-succinate (Cambridge Isotopes, Inc). 
Fluorocitrate (Sigma-Aldrich) was added at the indicated experiments at a final concentration 
of 0.5µM. Equal numbers of nuclei between the cell lysates labeling experiment and the nuclei 
labeling experiments were calculated based on counting using a Neubauer chamber. For the 
cell lysates experiment, the samples were collected immediately after the homogenization step 
(see section above) and the hypotonic buffer was adjusted to the modified buffer B by adding 
the missing compounds and the 13C-labeling substrates, as described above. For the nuclei 
experiments, isolated nuclei were re-suspended in 500 µl modified buffer B with the 13C-
labeling substrates. The nuclei or the cell lysates were placed in 12-well cell culture plates and 
incubated in the dark, at 37oC, for 5 hours. After incubation, the nuclei were collected and 
centrifuged at 1000g for 8min, at 4oC. The pellets were resuspended in 500 µl of ice cold PBS 
and centrifuged at 1000g for 8min, at 4oC. The supernatant was carefully aspirated and the 
nuclei were resuspended in 300µl of ice cold HPLC-grade methanol (Biosolve). The 
methanol/nuclei mixture was stored at -80oC until metabolite extraction (performed on the next 
day). For metabolite extraction, 10µl of ribitol (50µg/ml) (Alfa Aesar, UK) was added to the 
nuclei/methanol mixture and the samples were vortexed for 2 minutes. Subsequently, the 
samples were incubated at 72oC for 15min, followed by addition of 300 µl ice cold MilliQ water 
and vortex for 2 minutes. The samples were centrifuged at 15000rpm for 10 minutes, at 4oC, 
the supernatants were carefully transferred in glass vials (Agilent, Santa Clara, CA), dried in 
a speed-vac, and stored at -80oC until GC-MS analysis. 
Gas Chromatography - Mass Spectrometry (GC-MS) data acquisition and 
analysis1 
Dried polar metabolites were derivatized with 40 μl of 20 mg/mL methoxyamine 
hydrochloride (Alfa Aesar, UK) solution in pyridine for 90 min at 37oC, followed by reaction 
with 80 μL N-methyl-trimethylsilyl-trifluoroacetamide (MSTFA) (Alfa Aesar, UK) for 10 hours 
at room temperature, as justified in. GC-MS analysis was performed using a Shimadzu 
TQ8040 GC-(triple quadrupole) MS system (Shimadzu Corp.) equipped with a 30m x 0.25 mm 
x 0.25 µm DB-50MS capillary column (Phenomenex, USA). 1 μl of sample was injected in split 
mode (split ratio 1:5) at 250oC using helium as a carrier gas with a flow rate of 1 ml/min. GC 
oven temperature was held at 100oC for 4 min followed by an increase to 320oC with a rate of 
10oC/min, and a final constant temperature period at 320oC for 11 min. The interface and the 
ion source were held at 280oC and 230oC, respectively. The detector was operated both in 
                                                          
1 The following method part is based on the methods described on Strucko and colleagues160, and Blasche and 
colleagues169 where it was originally written by myself 
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scanning mode recording in the range of 50-600 m/z, as well as in MRM mode for specified 
metabolites. The metabolite quantification was carried out by calculating the area under the 
curve (AUC) of the identified marker ions of each metabolite. Natural abundance isotopes 
were corrected using the Isotope Correction Toolbox (ICT)156.   
Generation of Constructs 
Constructs containing the gene of interest fused to BioID2 and a FLAG epitope were 
generated via Gateway cloning technology (Invitrogen). Firstly, two destination vectors 
containing the BioID2 and FLAG for N-terminus fusion and C-terminus fusion were created. 
To achieve this, we used two destination vectors with the older version of BioID (pcDNA5-
pDEST-BioID-FLAG-N-term and pcDNA5-pDEST-BioID-FLAG-C-term, donated from Martin 
Beck, EMBL Heidelberg) and replaced it with the new and smaller version of BioID2 via Gibson 
assembly (New England Biolabs). Briefly, BioID2 in pcDNA3.1-BioID2-HA plasmid was PCR 
amplified with primers containing the FLAG epitope for N- or C-terminus integration (FLAG-
BioID2 or BioID2-FLAG). pcDNA5-pDEST-BioID-FLAG-N-term and pcDNA5-pDEST-BioID-
FLAG-C-term plasmids were amplified by PCR, excluding the BioID-FLAG region, and 
creating appropriate overlapping to the BioID2-FLAG or FLAG-BioID2 end fragments. One µl 
of the PCR products (15ng BioID2-FLAG or 15ng FLAG-BioID2, 7.5ng pcDNA5-pDEST---N-
term or 10ng pcDNA5-pDEST---C-term) were incubated with 2 µl Gibson assembly reaction 
mix at 50oC for 60 min. Two µl of the reaction were diluted with 8 µl water, and 4 µl of this 
dilution were used to transform One Shot ccdB Survival 2 T1R competent cells (Invitrogen). 
Transformants were selected with chloramphenicol (33 µg/ml) (Sigma-Aldrich) and ampicillin 
(100 µg/ml) (Sigma-Aldrich). The entry clones with the genes of interests (PDHB, ACO2, IDH2, 
IDH3G, IDH1 and OGDH) were purchased from the Human ORFeome Collection 
(Dharmacon). The final constructs were created by performing the LR recombination reaction 
between the destination vectors and the entry clones according to manufacturer’s instructions. 
Briefly, 1 µl of entry clone (~100ng) was combined with 1 µl of destination vector (~150ng) and 
2 µl of LR Clonase II reaction buffer into a final volume of 10 µl with TE buffer. The reaction 
was incubated at 25oC for 90 min followed by addition of 1 µl proteinase K and incubation at 
37oC for 10 min. One µl of the LR reaction was used to transform DH5α competent E. coli 
(Invitrogen) and transformants were selected with the appropriate antibiotics.  
All PCR conditions were defined using the http://webpcr.appspot.com/. All constructs 
were extracted using the QIAprep Spin Miniprep Kit (Qiagen). The final constructs were 
sequenced-verified by Sanger sequencing at Eurofins Genomics. An overview of all vectors 
and selection antibiotics, as well as primers can be found in Tables 1, 2 and 3.   
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Table 1: Destination vectors and entry clones used for the generation of the engineered 
constructs 
Constructs Type 
Selection 
Antibiotics 
Catalogue 
Number 
Source 
pcDNA3.1-BioID2-HA  Ampicillin #74224 Addgene 
pcDNA5-pDEST-
BioID-FLAG-N-term 
Destination 
Vector 
Ampicillin  
Martin Beck, EMBL 
Heidelberg 157 
pcDNA5-pDEST-
BioID-FLAG-C-term 
Destination 
Vector 
Ampicillin  
Martin Beck, EMBL 
Heidelberg 157 
pcDNA5-pDEST-
BioID2-FLAG-N-term 
Destination 
Vector 
Ampicillin  
Created for this study 
(see text) 
pcDNA5-pDEST-
BioID2-FLAG-C-term 
Destination 
Vector 
Ampicillin  
Created for this study 
(see text) 
PDHB 
Entry clone 
(pENTR221) 
Kanamycin 
 
OHS5894-
202496027 
Human ORFeome 
(Dharmacon) 
ACO2 
Entry clone 
(pENTR221) 
Kanamycin 
 
OHS5894-
202497317 
Human ORFeome 
(Dharmacon) 
IDH1 
Entry clone 
(pENTR221) 
Kanamycin 
 
OHS5894-
202498644 
Human ORFeome 
(Dharmacon) 
IDH2 
Entry clone 
(pENTR221) 
Kanamycin 
 
OHS5894-
202497544 
Human ORFeome 
(Dharmacon) 
IDH3G 
Entry clone 
(pENTR201) 
Kanamycin 
 
OHS5894-
202501324 
Human ORFeome 
(Dharmacon) 
OGDH 
Entry clone 
(pENTR221) 
Kanamycin 
 
OHS5894-
202498466 
Human ORFeome 
(Dharmacon) 
 
Cell Culture and generation of stable inducible cell lines  
Flp-In T-Rex HeLa cells were maintained under standard cultivation conditions (37oC, 
5% CO2) in high-glucose (5g/L) Dulbecco’s modified Eagle medium (DMEM, GlutaMax, 
Thermo Fischer Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Thermo Fischer Scientific). The parental cell line was grown with the addition of zeocin 
(50µg/ml) (Invitrogen) and blasticidin (5µg/ml) (Thermo Fisher Scientific), while the stable cell 
lines were grown under the presence of blasticidin (5µg/ml) and hygromycin (200µg/ml) 
(Invitrogen).  
The stable Flp-In T-Rex HeLa cell lines were generated using the X-tremeGENE 9 
DNA Transfection Reagent (Sigma-Aldrich) following the manufacturer’s instructions. Briefly, 
Flp-In T-Rex HeLa cells (passage 1) were seeded in 6-well plates (1.8 x 104 cells/well) in 
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complete DMEM without antibiotics. After 24h, the transfection mixture was prepared 
[consisted of 100 µl Opti-MEM (Gibco), 3 µl of X-tremeGENE 9 DNA Transfection Reagent, 
100 ng of plasmid with the construct of interest and 900 ng of pOG44 (Thermo Fisher 
Scientific)], incubated for 15 min at room temperature, and added in a drop-wise manner to 
the cells under gentle shaking. On the third day, the cells were expanded via trypsinization 
(Trypsin-EDTA, Gibco) into 150 mm plates, and the following day the medium was changed 
into complete DMEM with the addition of the selection antibiotics blasticidin (5µg/ml) and 
hygromycin (200µg/ml). The following weeks, the medium was replaced with fresh complete 
DMEM and antibiotics thrice per week. When large colonies were formed, the cells were 
trypsinized into the same plates and when 80% confluency was reached they were prepared 
for cryopreservation. For the cryopreservation, the cells were washed with PBS (Thermo 
Fischer Scientific), trypsinized, centrifuged at 500g for 5 min and re-suspended in DMEM 
supplemented with 20% fetal bovine serum and 10% DMSO (Sigma-Aldrich). The vials were 
placed into a freezing container (Mr. Frosty™, Thermo Fischer Scientific) for 24h at -80oC 
followed by transfer into a liquid nitrogen tank for long term storage.  
Table 2: Primers for generation of the engineered constructs and oligos 
Template Primers (5’-3’) 
Final 
Construct/Oligo 
pcDNA3.1-
BioID2-HA 
5’ACAAAGTGGTTGATTCTAGATTCAAGAACCTGATCT
GGCT3’ 
5’TCGTCATCGTCTTTGTAGTCGCTTCTTCTCAGGCTG
AACT3’ 
BioID2-FLAG 
pcDNA3.1-
BioID2-HA 
5’CGGATCCAGCTAGCGCCACCATGGACTACAAAGAC
GATGACGATAAATTCAAGAACCTGATCTGG3’ 
5’GCTTTTTTGTACAAACTTGTGCTTCTTCTCAGGCTGA
ACTCGCCG3’ 
FLAG-BioID2 
pcDNA5-
pDEST-BioID-
FLAG-C-term 
5’AGTTCAGCCTGAGAAGAAGCGACTACAAAGACGAT
GACGA3’ 
5’AGCCAGATCAGGTTCTTGAATCTAGAATCAACCACT
TTGTACA3’ 
pcDNA5-pDEST---
C-term 
pcDNA5-
pDEST-BioID-
FLAG-N-term 
5’AGTTCAGCCTGAGAAGAAGCACAAGTTTGTACAAAA
AAGCTGAACGAGAAACGTAAAATG3’ 
5’AGTTCAGCCTGAGAAGAAGCACAAGTTTGTACAAAA
AAGCTGAACGAGAAACGTAAAATG3’ 
pcDNA5-pDEST---
N-term 
 
BioID labeling and cell harvesting  
Flp-In T-Rex HeLa cells stably transfected with BioID2-FLAG-tagged constructs and 
wild type parental cells were seeded in 245mm plates (2.0 x 106 cells/plate) in complete DMEM 
without antibiotics. After 24h, the medium was supplemented with 0.13 µg/ml tetracycline 
(Sigma-Aldrich) for induction of protein expression. The following day, 13 µM biotin (Sigma-
Aldrich) was added for protein biotinylation, and after 24h the cells were harvested. For the 
harvesting, the cells were washed with 20 ml PBS, detached with 10ml trypsin-EDTA and 
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collected with 20ml complete medium. The collected cells were centrifuged at 500g for 5min 
at 4oC, re-suspended in 15ml PBS (4oC) and centrifuged again under the previous conditions. 
Once the supernatant was aspirated, the cell pellets were frozen on dry ice and stored at -
80oC until further processing. The final number of collected cells was 2x107 per plate. For each 
stable cell line, four replicates were collected.  
Table 3: Sequencing primers for the engineered constructs 
Final Constructs Sequencing Primers 
PDHB-BioID2-FLAG, IDH1- BioID2-FLAG, 
IDH2- BioID2-FLAG, IDH3G- BioID2-FLAG 
5’CGCAAATGGGCGGTAGGCGTG3’ 
5’CTCACGTTCCACTCCTTCAG3’ 
FLAG-BioID2-PDHB, FLAG-BioID2-IDH1,  
FLAG-BioID2-IDH2, FLAG-BioID2-IDH3G, 
5’GCATCAAGGAGATCCTGAGC3’ 
5’GGGCAAACAACAGATGGCTG3’ 
ACO2-BioID2-FLAG 
5’CGCAAATGGGCGGTAGGCGTG3’ 
5’CTCACGTTCCACTCCTTCAG3’ 
5’CCTGAACTTCTTGCCATCCG3’ 
FLAG-BioID2-ACO2 
5’GCATCAAGGAGATCCTGAGC3’ 
5’GGGCAAACAACAGATGGCTG3’ 
5’CCTGAACTTCTTGCCATCCG3’ 
OGDH-BioID2-FLAG 
5’CGCAAATGGGCGGTAGGCGTG3‘ 
5’CTCACGTTCCACTCCTTCAG3‘ 
5’GCCACTTTGCACACGTACATG3‘ 
5’GCAGATGAACTGGTCGATG3‘ 
FLAG-BioID2-OGDH 
5’GCATCAAGGAGATCCTGAGC3’ 
5’GGGCAAACAACAGATGGCTG3’ 
5’GCCACTTTGCACACGTACATG3‘ 
5’GCAGATGAACTGGTCGATG3‘ 
 
Affinity purification of biotinylated proteins  
The affinity purification of the biotinylated proteins was adapted from the method 
developed by Mackmull et al 2017157 with slight modifications. The frozen cell pellets were re-
suspended in 8ml of lysis buffer (4oC) [50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 
0.1% SDS, 1 mM EDTA, 1mM EGTA, 1 mM PMFS (Sigma-Aldrich), 1 mg/ml Aprotinin (Carl-
Roth), 0.5 mg/ml Leupeptin (Carl-Roth), 250 Units HS-Nuclease (Accelagen)] and incubated 
for 1h at 4oC under constant mild rotation (30 rpm). The cell lysates were sonicated at 4oC for 
30 sec x 5 times with 30 sec rest in-between, and subsequently centrifuged at 17000g for 30 
min at 4oC to remove any insoluble material. 80 µl of Streptavidin Sepharose High 
Performance beads (GE Healthcare) were equilibrated in 1ml of lysis buffer for 30 min at 4oC 
under constant mild rotation (30 rpm). The equilibrated beads were centrifuged at 2000g for 5 
min at 4oC, then transferred to the lysed supernatants and incubated for 3h at 4oC under 
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constant mild rotation (30 rpm). After the incubation, the beads were centrifuged at 2000g for 
5 min at 4oC and 7.5 ml of the supernatant were discarded. The remaining beads-lysates were 
transferred to a Spin Column (Pierce, Thermo Fischer Scientific), washed once with 800 µl of 
lysis buffer and then five times with 700 µl of 50 mM ammonium bicarbonate pH 8.3. After the 
washing, the column was plugged and the beads were transferred to a fresh eppendorf tube 
with 300 µl of 50 mM ammonium bicarbonate pH 8.3. The same procedure was repeated two 
more times to ensure all beads were collected. One µg of Sequencing Modified Trypsin 
(Promega) was added and the samples were incubated at 37 °C for 16 hr under constant 
shaking (500 rpm). The following day, 0.5 µg of trypsin were added and the beads were 
incubated for 2 additional hours under the same conditions. Following incubation, the beads 
were transferred to a new Spin Column and the digested peptides were eluted with two times 
with 150 μl of 50 mM ammonium bicarbonate pH8. The eluted peptides were dried in a speed-
vac and stored at -80oC until further processing. All steps were performed using low protein 
binding tips (Starlab) and low protein binding eppendorf tubes (Thermo Fischer Scientific). 
Sample preparation and TMT labeling for mass spectrometry2 
Dried samples were dissolved in 1% formic acid with 4% acetonitrile and subjected to 
OASIS® HLB µElution Plate (Waters) for desalting according to manufacturer’s instructions. 
Desalted peptides were reconstituted in 50 mM HEPES (pH 8.5) and labelled with 
TMT10plex158 Isobaric Label Reagent (Thermo Fischer Scientific) according the 
manufacturer’s instructions. For further sample clean up an OASIS® HLB µElution Plate 
(Waters) was used. Offline high pH reverse phase fractionation was carried out on an Agilent 
1200 Infinity high-performance liquid chromatography system, equipped with a Gemini C18 
column (3 μm, 110 Å, 100 x 1.0 mm, Phenomenex)159. 
Mass spectrometry data acquisition2 
An UltiMate 3000 RSLC nano LC system (Dionex) fitted with a trapping cartridge (µ-
Precolumn C18 PepMap 100, 5µm, 300 µm i.d. x 5 mm, 100 Å) and an analytical column 
(nanoEase™ M/Z HSS T3 column 75 µm x 250 mm C18, 1.8 µm, 100 Å, Waters). Trapping 
was carried out with a constant flow of solvent A (0.1% formic acid in water) at 30 µL/min onto 
the trapping column for 6 minutes. Subsequently, peptides were eluted via the analytical 
column with a constant flow of 0.3 µL/min with increasing percentage of solvent B (0.1% formic 
acid in acetonitrile) from 2% to 4% in 4 min, from 4% to 8% in 2 min, then 8% to 28% for a 
further 96 min, and finally from 28% to 40% in another 10 min. The outlet of the analytical 
                                                          
2 The following method part was provided from Mandy Rettel and Frank Stein, Proteomics Core Facility, EMBL, 
Heidelberg, Germany 
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column was coupled directly to a QExactive plus (Thermo Fischer Scientific) mass 
spectrometer using the proxeon nanoflow source in positive ion mode. 
The peptides were introduced into the QExactive plus via a Pico-Tip Emitter 360 µm 
OD x 20 µm ID; 10 µm tip (New Objective) and an applied spray voltage of 2.3 kV. The capillary 
temperature was set at 320°C. Full mass scan was acquired with mass range 350-1400 m/z 
in profile mode in the FT with resolution of 70000. The filling time was set at maximum of 100 
ms with a limitation of 3x106 ions. Data dependent acquisition (DDA) was performed with the 
resolution of the Orbitrap set to 35000, with a fill time of 120 ms and a limitation of 2x105 ions. 
A normalized collision energy of 32 was applied. A loop count of 10 with count 1 was used 
and a minimum AGC trigger of 2e2 was set. Dynamic exclusion time of 30 s was used. The 
peptide match algorithm was set to ‘preferred’ and charge exclusion ‘unassigned’, charge 
states 1, 5 - 8 were excluded. MS2 data were acquired in profile mode160. 
Mass spectrometry data analysis2 
IsobarQuant161 and Mascot (v2.2.07) were used to process the acquired data, which 
was searched against a Uniprot Homo sapiens proteome database (UP000005640) 
containing common contaminants and reversed sequences. The following modifications were 
included into the search parameters: Carbamidomethyl (C) and TMT10 (K) (fixed 
modification), Acetyl (N-term), Oxidation (M) and TMT10 (N-term) (variable modifications). For 
the full scan (MS1) a mass error tolerance of 10 ppm and for MS/MS (MS2) spectra of 0.02 
Da was set. Further parameters were set: Trypsin as protease with an allowance of maximum 
two missed cleavages: a minimum peptide length of seven amino acids; at least two unique 
peptides were required for a protein identification. The false discovery rate on peptide and 
protein level was set to 0.01. 
Statistical Analysis and Identification of proximal interactors2 
Raw data of IsobarQuant were loaded into R (ISBN 3-900051-07-0). As a quality 
criteria, only proteins which were quantified with at least two different unique peptides were 
used for downstream analysis. The “signal_sum” columns of the “proteins”-output sheet from 
IsobarQuant were cleaned for potential batch-effects with limma162 and subsequently 
normalized with vsn (variance stabilization)163. Missing values were imputed with the impute 
function (method = “knn”) from the MSNBase package164. Limma was employed again to test 
for differential abundance. Each engineered cell line (stable cells with inducible expression of 
the protein of interest fused to biotin ligase) was compared to wild type HeLa and a protein 
was considered a proximal interactor with a log2 fold change ≥ 0.6 and a (Benjamini-Hochberg) 
adjusted p value ≤ 0.1. These results were further refined by removing known contaminants 
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from the CRAPome165 database detected in experiments performed on HeLa cell lines with a 
cutoff frequency ≥ 20% - proteins measured with a log2 fold change ≥ 1.32 (engineered HeLa 
to wild type HeLa) were kept as proximal interactors. To further exclude unspecific proteins as 
a result of the exogenous expression of the biotin ligase, the engineered cells were compared 
to the engineered cells with N-fused IDH2, and only the proteins detected as significant (using 
the same criteria as above) in this comparison in addition to the comparison with wild type 
HeLa were kept in the list of proximal interactors. To define the higher specificity interactome 
each engineered cell line was compared to wild type parental HeLa, N-fused IDH2 and C-
fused IDH2 or C-fused PDHB engineered cell lines, and the common significant proteins in all 
comparisons were included in the list of proximal interactors.  
Gene ontology enrichment analysis 
For the gene ontology enrichment analysis, the g:Profiler112,113 (version 
e94_eg41_p11_ff2a873) was used with the following parameters: significance threshold, 
Benjamini-Hochberg FDR; user threshold, 0.05; statistical domain scope, custom, using the 
entire proteomics dataset as a background list. 
Dotplot generation 
For the dotplot generation, the ProHits-viz166 platform was used for the higher 
specificity interactome. The data contained the log2fold changes of each detected biotinylated 
protein as derived from the comparisons between each engineered cell line to the wild type 
HeLa cells along with the respective adjusted p values estimated by limma162 analysis (see 
above). The following parameters were used: score type, adjusted p value defined by limma 
analysis; primary filter, 0.01; secondary filter, 0.1; no clustering was utilized.  
Cytoscape visualization 
Cytoscape123 3.6.1 was used for the visualization of the higher specificity interactome 
and GO enrichment analysis was performed utilizing the ClueGO122 plug-in. The uploaded 
data file contained the log2fold changes of each detected biotinylated protein as derived from 
the comparisons between each engineered cell line to the wild type HeLa cells along with the 
respective adjusted p values estimated by limma162 analysis (see above).  
Immunofluorescence and Imaging 
For immunofluorescence analysis, cells were seeded in 8-well Nunc Lab-Tek II 
coverglass chambers (Sigma-Aldrich) (2700 cells/well in 300 µl medium/well) and the 
induction of protein expression and biotinylation was performed as described before. The cells 
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were washed thrice with PBS, fixed with 4% formaldehyde (Image-iT, Invitrogen) for 10 min, 
followed by three washing steps with PBS. Subsequently, the cells were permeabilized with 
0.2% Triton-X100 for 20 min, washed thrice with PBS and blocked (0.1% BSA, 0.3M glycine, 
0.1% Tween-20 in PBS) for 1h at room temperature. Incubation with primary antibodies in 
blocking solution was performed overnight in a humidified chamber at 4oC: the biotinylated 
proteins were detected with the streptavidin Alexa Fluor 488 (Thermo Fischer Scientific, 
S11223), the bait proteins with mouse anti-FLAG (Sigma-Aldrich, F1804) as well as with 
specific antibodies that bound to the endogenous proteins. The following day, the cells were 
washed three times with PBS and incubated with secondary antibodies in blocking solution for 
1hr at room temperature in a dark room. Following three washing steps in PBS, the cells were 
stained with Hoechst (2.6 µg/ml) (Thermo Fischer Scientific, 62249) for 20 min at room 
temperature in the dark, then washed three times with PBS and finally saved in PBS with 
0.02% sodium azide (Sigma-Aldrich) at 4oC. Sample images were acquired at the Advanced 
Light Microscopy Facility at EMBL, Heidelberg with a Leica TCS SP8 DLS system using a 63x 
oil objective, and analyzed with LAS X (Leica) and ImageJ software. A list of primary and 
secondary antibodies along with the respective dilutions and combinations is presented in 
Table 4.  
Table 4: Immunofluorescence Antibodies Conditions 
Cell line Primary Incubation Secondary Incubation 
PDHB-BioID2, 
OGDH-BioID2, 
IDH3G-BioID2, 
Parental HeLa 
streptavidin Alexa Fluor 488 (1:100) and 
mouse anti-FLAG (1:100) 
anti-mouse Alexa Fluor 647 
(1:200) (Thermo Fischer 
Scientific, A28181) 
streptavidin Alexa Fluor 488 (1:100) and 
rabbit anti-OGDH (1:100) (Sigma-Aldrich, 
HPA020347) 
anti-rabbit Alexa Fluor 647 
(1:200) (Thermo Fisher 
Scientific, A27040) 
streptavidin Alexa Fluor 488 (1:100) and 
rabbit anti-IDH3G (1:400) (Sigma-Aldrich, 
HPA002017) 
anti-rabbit Alexa Fluor 647 
(1:800) 
ACO2-BioID2, 
IDH2-BioID2, 
Parental HeLa 
streptavidin Alexa Fluor 488 (1:500) and 
mouse anti-FLAG (1:100) 
anti-mouse Alexa Fluor 647 
(1:200) 
streptavidin Alexa Fluor 488 (1:500) and 
rabbit anti-Aconitase 2 (1:500) (Abcam, 
ab129069) 
anti-rabbit Alexa Fluor 647 
(1:1000) 
IDH1-BioID2, 
Parental HeLa 
streptavidin Alexa Fluor 488 (1:1000) and 
mouse anti-FLAG (1:100) 
anti-mouse Alexa Fluor 647 
(1:200) 
streptavidin Alexa Fluor 488 (1:1000) - 
 
Immunoblotting 
For immunoblotting, cell samples or isolated nuclei were collected as described in the 
respective sections above. The samples were lysed in sample buffer (62.5 mM Tris pH 6.8, 
2% SDS, 10% glycerol, 0.0006% Bromophenol Blue, 5% β-Mercaptoethanol), incubated at 
95oC for 5 min and sonicated to shear the DNA. The proteins were separated on 4–20% 
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gradient gels (Mini-PROTEAN® TGX™ Precast Protein Gels, Biorad). Prior transfer, the gel, 
the nitrocellulose membrane (Sigma-Aldrich) and the blot filter papers (Biorad) were 
equilibrated in transfer buffer (25 mM Tris, 192 mM glycine pH 8.3, 20% methanol, 0.04 % 
SDS) for 15 min with agitation. For the transfer, the Trans-Blot Turbo System (Biorad) with the 
STANDARD SD protocol followed by the Mixed MW program was used. The membrane was 
then blocked in 1% BSA in PBST (PBS, 0.02% Tween-20) for 1h at room temperature followed 
by overnight incubation at 4oC with primary antibodies diluted in 1% BSA in PBST under 
agitation. The following day, the membrane was washed thrice with PBST, incubated for 1h at 
room temperature with the appropriate secondary antibody in 1% BSA in PBST, and then 
washed thrice with PBST. Finally, the membrane was developed using the Pierce ECL Plus 
Western Blotting Substrate (Thermo Fischer Scientific) and imaged in a ChemiDoc MP 
Imaging System (Biorad). The antibodies used for immunoblot of the stable cell lines were the 
following: anti-Biotin HRP-linked (1:3000) (Cell Signaling Technology, #7075), streptavidin 
HRP-linked (1:3000) (Thermo Fischer Scientific, 21130), mouse-anti FLAG (1:1000) (Sigma-
Aldrich, F1804) and anti-mouse HRP-linked (1:2000) (Abcam, ab205719). For the nuclei 
immunoblots, the following antibodies were used: rabbit anti-IDH2 (1:1000) (Abcam, 
ab129180), rabbit anti-COXIV (1:1000) (Cell Signaling Technology, #8674), rabbit anti-
cytochrome c (1:1000) (Cell Signaling Technology, #8674), rabbit anti-beta III tubulin (1:1000) 
(Abcam, ab18207) and anti-rabbit HRP-linked (1:2000) (Abcam, ab205718).  
Chapter II and Chapter III – Materials and Methods 
Three dimensional cell cultures3 
Three-dimensional cell cultures were established according to the published protocol167 with 
some modifications. Primary mammary epithelial cells were obtained from 8 weeks old virgin 
females of described mouse strains, through digestion of mammary glands in 5 mL of digestion 
media (Lonza/Amaxa DMEM/F12 1:1 Mixture with HEPES, L- Gln, BE12-719F), 
supplemented with HEPES to the final concentration of 25 mM, 150 U/mL Collagenase type 
3 (Worthington, LS004183), 20 µg/mL Liberase Blendzyme 2 (Roche, 05401020001) and 5 
ml of Penicillin/Streptomycin (Gibco Life Technologies, 15140-122). After digestion for 15-16 
hours at 37oC in 5 % (vol/vol) CO2 atmopshere, in loosely capped 50 mL polypropylene 
conical tubes, washing step with 45 mL of phosphate-buffered saline (PBS) was performed. 
Upon centrifugation at room temperature, 1000 rpm for 5 min, interphase between upper fat 
layer and cell pellet was removed and 5 mL of 0.25 % trypsin-EDTA (Invitrogen, 25200-056) 
was added. Suspension was incubated for 40 min at 37oC, 5 % CO2 in loosely capped tubes, 
                                                          
3 The following method part was written by Ksenija Radić Shechter 
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followed by the wash with 25 mL of STOP media (Lonza/Amaxa DMEM/F12 1:1 Mixture with 
HEPES, L-Gln, BE12-719F supplemented with HEPES to the final concentration of 25 mM 
and 10 % Tet System Approved Fetal Bovine Serum, Biowest, S181T) and treatment with 5-
15 mg/mL DNase I (ThermoFisher, 18068015). After another centrifugation step at room 
temperature, 1000 rpm for 5 min, dissociated cells were resuspended in MEBM media (Lonza, 
Mammary Epithelial Cell Basal Medium CC-3151 with supplements from Mammary Epithelial 
Cell Medium BulletKit CC-3150) and plated onto collagen-coated plates (BD Biosciences, 
356400) for selection of epithelial cells. Next day cells were washed with PBS and the 
remaining ones treated with 500 µl of 0,25 % trypsin-EDTA until detachment. Trypsin was 
inactivated with 9 mL of STOP media (described above), followed by centrifugation step at 
room temperature, 1000 rpm for 5 min. Cell pellets were resuspended in PBS, counted, and 
mixed rapidly on ice with the prepared Matrigel- collagen mixture – Cultrex 3D Culture Matrix 
Basement Membrane Extract (Biozol, TRE- 3445-005-01) and 1,5 mg/mL Cultrex 3D Collagen 
I rat tail (TEMA Ricerca, 3447-020- 01). Mixed droplets in volume of 100 µl containing 12 500 
primary mouse mammary epithelial cells were dispensed into flat bottom wells (Corning 
CellBIND 12 Well Clear Multiple Well Plates, 3336) or chambered cover glass slides 
(ThermoFisher Scientific, Nunc LabTek II Chambered Cover glass, 155379). After gel 
solidifying for 35-40 min at 37oC, 1.5 ml of MEBM serum-free media (supplemented with 2 mL 
of bovine pituitary extract, 0.5 mL of hEGF, 0.5 mL of hydrocortisone, 0.5 mL of GA-1000, 0.5 
mL Insulin from Mammary Epithelial Cell Medium BulletKit CC-3150) was added to each well. 
Doxycycline (Sigma, Doxycycline hyclate, D9891) was titrated to lower concentration of 200 
ng/ml. For metabolic analyses, from the start of experiment until collection, media was used 
in volume of 1 mL and changed every day at the precise times. 
Three dimensional cell cultures experiments - Cell and Spent Growth 
Media Collection and Metabolite Extraction4 
Organoid structures were freed from Matrigel upon digestion for 1,5 h at 37oC with 3 
µl of liberase and 3 µl of collagenase added to the media. 3 wells were pooled per 
condition/technical replicate, washed three times with PBS, centrifuged at 1000 rpm for 2 min, 
at room temperature, and quenched with 200 µl cold (-80oC) HPLC-grade methanol (Biosolve). 
Samples were stored at -80oC until metabolite extraction. For metabolite extraction, 10µl of 
ribitol (50µg/ml) (Alfa Aesar, UK) was added to the cell/methanol mixture and the samples 
were vortexed for 2 minutes. Subsequently, the samples were incubated at 72oC for 15min, 
followed by addition of 200 µl ice cold MilliQ water and vortex for 2 minutes. The samples were 
centrifuged at 15000rpm for 10 minutes at 4oC, the supernatants were carefully transferred in 
                                                          
4 The following method part is based on the method described in Havas and colleagues131 where it was originally 
written by me 
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glass vials (Agilent, Santa Clara, CA), dried in a speed-vac, and stored at -80oC until GC-MS 
analysis. 50µl of the spent growth medium of each well and the last washing solution of each 
sample were also collected and quenched with 100µl of cold (-80oC) HPLC-grade methanol 
(Biosolve). Metabolite extraction from the spent growth media was performed as described 
above with the following difference: instead of 200 µl MilliQ water, 100µl were added.  
In vivo mammary glands experiments5   
For glucose labeling experiment, mammary glands were dissected, minced and 
digested for 2 hours at 37oC using collagenase and liberase enzymes, then were cultured for 
8 hours at 37oC in 5 % (vol/vol) CO2 atmopshere, in DMEM glucose- and pyruvate-free media 
(ThermoFisher Scientific, 11966025) supplemented with 4,5 g/L labeled D- Glucose U-13C, 
99% (Cambridge Isotope Laboratories, Inc., CLM-1396-1) and 2 mL of bovine pituitary extract, 
0.5 mL of hEGF, 0.5 mL of hydrocortisone, 0.5 mL of GA-1000, 0.5 mL insulin from Mammary 
Epithelial Cell Medium BulletKit CC-3150. For non-labeled GCMS metabolomics experiment, 
mammary glands were dissected and cultured for 8 hours at 37oC in 5 % (vol/vol) CO2 
atmosphere, in DMEM, High Glucose (4,5 g/L glucose) GlutaMAX (Gibco, 10569044) 
supplemented with 2 mL of bovine pituitary extract, 0.5 mL of hEGF, 0.5 mL of hydrocortisone, 
0.5 mL of GA-1000, 0.5 mL insulin from Mammary Epithelial Cell Medium BulletKit CC-3150. 
Extracellular metabolites were collected and snap-frozen in liquid nitrogen; for intracellular 
metabolites harvesting, cells were quickly washed two times in PBS and quenched with cold 
methanol. Metabolites were extracted using the method described in the above section. 
Gas Chromatography - Mass Spectrometry (GC-MS) data acquisition and 
analysis6 
Unlabelled samples. Dried polar metabolites were derivatized with 50 μl of 20 mg/mL 
methoxyamine hydrochloride (Alfa Aesar, UK) solution in pyridine for 90 min at 37oC, followed 
by reaction with 100 μL N-methyl-trimethylsilyl-trifluoroacetamide (MSTFA) (Alfa Aesar, UK) 
for 10 hours at room temperature, as justified in168. GC-MS analysis was performed using a 
Shimadzu TQ8040 GC-(triple quadrupole) MS system (Shimadzu Corp.) equipped with a 30m 
x 0.25 mm x 0.25 µm DB-50MS capillary column (Phenomenex, USA). 1 μl of sample was 
injected in split mode (split ratio 1:20) at 250oC using helium as a carrier gas with a flow rate 
of 1 ml/min. GC oven temperature was held at 100oC for 4 min followed by an increase to 
320oC with a rate of 10oC/min, and a final constant temperature period at 320oC for 11 min. 
The interface and the ion source were held at 280oC and 230oC, respectively. The detector 
                                                          
5 The following method part is based on Ksenija Radić Shechter, PhD thesis 
6 The following method part is based on the methods described on Strucko and colleagues160, and Blasche and 
colleagues169 where it was originally written by me 
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was operated both in scanning mode recording in the range of 50-600 m/z, as well as in MRM 
mode for specified metabolites. The metabolite identification was based in an in-house 
database were standards were used to define the retention time and the mass spectrum for 
all mentioned metabolites. Both information were subsequently used to identify the 
metabolites in the biological samples. The metabolite quantification was carried out by 
calculating the area under the curve (AUC) of the identified marker ion of each metabolite 
normalized to the area of ribitol’s marker ion 319. Subsequently, areas were normalized to 
total metabolite levels. To identify the statistically significant altered metabolites limma162 
analysis was performed, and the statistically significant metabolites were defined using the 
following criteria: Benjamini-Hochberg FDR adjusted p value ≤ 0.01 and a log2 fold change 
(condition/control) ≥ 1or ≤ -1.  
13C labelled samples. For the 13C isotope tracing experiments, the dried polar 
metabolites were derivatized with 50 μl of 20 mg/mL methoxyamine hydrochloride (Alfa Aesar, 
UK) solution in pyridine for 90 min at 37oC, followed by reaction with 100 μL N-tert-
Butyldimethylsilyl-N-methyltrifluoroacetamide with 1 % tert- Butyldimethylchlorosilane 
(TBDMS) (Sigma-Aldrich) for 1h at 60oC. The samples remained at room temperature until 
GC-MS analysis. The GC-MS was operated using the same conditions as described in the 
section above, with the following difference: GC oven temperature was held at 100oC for 3 
min followed by an increase to 300oC with a rate of 3.5oC/min, and a final constant temperature 
period at 300oC for 10 min. The metabolite quantification was carried out by calculating the 
area under the curve (AUC) of the identified marker ions of each metabolite, and the natural 
abundance isotopes were corrected using the Isotope Correction Toolbox (ICT)156.  
NOS enzymatic assay 
Mammary glands were dissected and homogenized in NOS assay buffer and further 
processed following the Nitric Oxide Synthase Activity Assay kit (Abcam, ab211083) protocol 
for measuring enzymatic activity of nitric oxide synthase (NOS). 
Two dimensional cell cultures experiments - Cell and Spent Growth 
Media Collection and Metabolite Extraction 
SNU-389 cells seeded on 10 cm dishes (90000 c/cm²), after 6 h they were starved 
overnight in RPMI 1640 (Gibco #31870), 2 mM L-Glutamine, 1% FCS. On the next day 
medium was changed to assay medium RPMI 1640 (Gibco #31870), 2 mM L-Glutamine, 5 % 
FCS and cells were treated with 0.3% DMSO, 2.5 µM LDHi, 1 µM MCTi, 2.5 µM LDHi+1 µM 
MCTi, for 1 and 4 h. For isotope tracing experiments, the same conditions were used as before 
utilizing [U-13C]-glucose and the [U-13C]-glutamine labeled media, and cells were collected for 
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1h, 2h, 4h, 6h and 8h after inhibitors treatment. Prior to cell collection, 2ml of spent growth 
medium was collected for extracellular metabolomics. Subsequently, the growth medium was 
removed, the cells were washed thrice with 10 ml ice cold PBS. The cells were then quenched 
using 2 ml ice-cold HPLC-grade methanol (Biosolve). Next, the cells were scraped off the 
plate, another 2 ml of ice-cold HPLC-grade methanol was added to collect any remaining cells 
and the samples were stored at -80oC until metabolite extraction. For metabolite extraction, 
10µl of ribitol (50µg/ml) (Alfa Aesar, UK) was added to the cells/methanol mixture and the 
samples were vortexed for 2 minutes. Subsequently, the samples were incubated at 72oC for 
15min, followed by addition of 4 ml ice cold MilliQ water and vortex for 2 minutes. The samples 
were centrifuged at 15000rpm for 10 minutes, at 4oC, the supernatants were carefully 
transferred in glass vials (Agilent, Santa Clara, CA), dried in a speed-vac, and stored at -80oC 
until GC-MS analysis. For the metabolomics acquisition and analysis, see the sections before. 
The contribution of glucose to TCA cycle was calculated as the ratio of total carbon contribution 
(FC) in citrate to total carbon contribution (FC) in pyruvate. Total carbon contribution (FC) was 
calculated using the following equation: ∑ 𝑖 ∗ 𝑚𝑛𝑖=0 𝑖/(𝑛 ∗ ∑ 𝑚𝑖
𝑛
𝑖=0 ), where n is the number of 
carbons in a metabolite, i the different mass isotopomers and m the abundance of a certain 
mass. 
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AcCoA acetyl-coenzyme A 
ACLY ATP citrate lyase 
ACO1 aconitase 1 
ACO2 aconitase 2 
akg alpha-ketoglutarate 
akgM3 alpha-ketoglutarate M3 isotopomer 
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glu glutamate 
GOT1 glutamic-oxaloacetic transaminase 1 
GOT2 glutamic-oxaloacetic transaminase 2 
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IDH2 isocitrate dehydrogenase 2 [NADP+] 
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IDH3G isocitrate dehydrogenase 3 [NAD+] subunit gamma 
lac lactate 
mal malate 
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MDH1 malate dehydrogenase 1 
MDH2 malate dehydrogenase 2 
ME1 malic enzyme 1 
ME2 malic enzyme 2 
ME3 malic enzyme 3 
N-ac-asp N-acetyl-aspartate 
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PDC pyruvate dehydrogenase complex 
PYC pyruvate carboxylase 
pyr pyruvate 
pyrM3 pyruvate M3 isotopomer 
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sucM4 succinate M4 isotopomer 
TCA cycle tricarboxylic acid cycle 
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Appendix 
 
Figure 29: Mass isotopomers analysis for metabolic intermediates in cell lysates incubated with [U-13C]-
pyruvate for 5 hours. The y axis indicate the percent of labeling. M0 to Mn indicates the different mass isotopomers 
(M0 denotes that zero carbons are labeled, and Mn denotes that n number of carbons are labeled) (The figure is 
related to Chapter I). 
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Figure 30: Pairwise Pearson correlation analysis of the proximal interactome of TCA cycle enzymes (the figure 
is related to Chapter I). 
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Figure 31: Metabolic alterations in control (never induced and wild-type), tumor and residual cells. Hierarchical 
clustering (Pearson correlation) on significantly altered metabolites in residual and tumor populations compared to 
the control state. (a) extracellular spent growth media samples, and (b) intracellular samples. The results are based 
on targeted GC-MS measurements (the figure is related to Chapter II). 
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Figure 32: Glutamine and glucose uptake changes after treatment with the LDHA inhibitor (LDHi) or MCT1/2 
inhibitor (MCTi) compared to the control cells (DMSO-treated). The barplots represent the fold change of glutamine 
or glucose extracellular concentration levels at 6h to 1h & 2h time points. One representative experiment is depicted 
(the figure is related to Chapter III). 
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Table 5: Top GO term for cellular compartments of the proximal interactors of the engineered 
proteins 
Cellular Compartment GO term ID adjusted p value Constructs 
mitochondrion GO:0005739 2.31E-142 PDHB* 
mitochondrion GO:0005739 1.07E-144 ACO2* 
mitochondrial part GO:0044429 1.31E-59 IDH3G* 
mitochondrial protein complex GO:0098798 3.56E-34 OGDH* 
mitochondrion GO:0005739 2.86E-153 IDH2* 
cytosol GO:0005829 1.19E-16 IDH1* 
chaperone complex GO:0101031 5.50E-10 *PDHB 
cytoskeleton GO:0005856 4.41E-11 *OGDH 
outer mitochondrial membrane 
protein complex GO:0098799 0.0004273 *IDH2 
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Table 6: Overview of higher specificity proximal interactors (Chapter I) 
IDH3G* OGDH* ACO2* 
IDH3G* & 
OGDH* 
OGDH* & 
ACO2* 
IDH3G* & OGDH* 
& ACO2* 
IDH3G-bait MRPS36 ACO2-bait SRSF1 DLD RBMX 
IDH3A SDF4 PDK2 SSRP1 DLST TOP2B 
IDH3B SNRPD3 ATP5D SUPT16H  HMGA1 
RUVBL1 TMOD3 PDK3 GAR1 
 
 
RUVBL2 NOL11 PDK1 TRA2B 
 
 
NXN RPL7L1 MGME1 DDX27 
 
 
CCT8 NOP58 MDH2 UBTF 
 
 
IDH1-bait SMARCA5 PREPL HNRNPDL 
 
 
UTP14A KRR1 HSPE1 PARP1 
 
 
PSMB6 DKC1 MRPL28 FTSJ3 
 
 
PABPN1 EBNA1BP2 MRPS16 HNRNPA1 
 
 
 
PUM3 MRPL57 NOP2 
 
 
 
PDCD11 
 
RRS1 
 
 
 
CHD1 
 
HNRNPA2B1 
 
 
 
DNTTIP2 
 
NIFK 
 
 
 
RPF2 
 
NOP56 
 
 
 
YTHDC1 
 
CBX5 
 
 
 
MYO1C 
 
DHX9 
 
 
 
NSA2 
 
HNRNPUL2 
 
 
 
HEATR1 
 
TOP2A 
 
 
 
TBL3 
 
HIST1H1B 
 
 
 
DDX18 
 
RALY 
 
 
 
SAP18 
 
SNU13 
 
 
 
WDR12 
 
SRSF10 
 
 
 
BRIX1 
 
HNRNPA3 
 
 
 
FBL 
 
MKI67 
 
 
 
MYH9 
 
BAZ1B 
 
 
 
MYL6 
 
HNRNPC 
 
 
 
ACTC1 
 
H2AFZ|H2AFV 
 
 
 
HIST1H1E 
 
PSIP1 
 
 
 
RBM12B 
 
SAFB 
 
 
 
UTP18 
 
HIST1H4A 
 
 
 
WDR46 
 
SLTM 
 
 
 
 
 
RSL1D1 
 
 
 
 
 
H2AFY 
 
 
   
PHIP 
 
 
   
SAFB2 
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